Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system

Description

FIELD OF THE INVENTION

The present invention relates to neurostimulation treatment systems and associated devices, as well as methods and devices for training clinicians, instructors, or other users of such treatment systems.

BACKGROUND OF THE INVENTION

Treatments with implantable neurostimulation systems have become increasingly common in recent years. While such systems have shown promise in treating a number of conditions, effectiveness of treatment may vary considerably between patients. A number of factors may lead to the very different outcomes that patients experience, and viability of treatment can be difficult to determine before implantation. For example, stimulation systems often make use of an array of electrodes to treat one or more target nerve structures. The electrodes are often mounted together on a multi-electrode lead, and the lead implanted in tissue of the patient at a position that is intended to result in electrical coupling of the electrode to the target nerve structure, typically with at least a portion of the coupling being provided via intermediate tissues. Other approaches may also be employed, for example, with one or more electrodes attached to the skin overlying the target nerve structures, implanted in cuffs around a target nerve, or the like. Regardless, the physician will typically seek to establish an appropriate treatment protocol by varying the electrical stimulation that is applied to the electrodes.

Neurostimulation systems are by their very nature complex and may provide reduced to no benefit to patients if adequate training is not provided to a clinician who is tasked with programming the neurostimulation systems (or to those who are instructing the clinician on how to program the neurostimulation systems). Besides simply reading manuals or viewing videos, adequate training requires practical “hands-on” training. However, training using actual pulse generators may not be feasible, at least in part due to the costs associated with these devices. As such, it would be particularly advantageous to provide systems and methods that can simulate pulse generators. Such devices may be used in place of expensive pulse generators. The resulting low-cost training system may be sufficiently available such that a larger number of clinicians or instructors may be able to have access to practical training for longer periods of time.

BRIEF SUMMARY OF THE INVENTION

The present invention generally relates to neurostimulation treatment systems and associated devices and methods, and in particular to systems and methods for simulating tasks related to neurostimulation procedures. The present invention has particular application to sacral nerve stimulation treatment systems configured to treat bladder and bowel related dysfunctions. It will be appreciated however that the present invention may also be utilized for the treatment of pain or other indications, such as movement or affective disorders, as will be appreciated by one of skill in the art.

In some embodiments, a trainer device may be coupled (wirelessly or via a wired connection) to a neurostimulator programmer (NP). The NP may be a device configured to program or adjust parameters of one or more neurostimulators (for example, an IPG or an EPG). For example the NP may be a clinician programmer. The trainer device may be a device that is configured to simulate the one or more neurostimulators. In some embodiments, the trainer device may transmit simulated neurostimulator information to the NP, wherein the simulated neurostimulator information comprises one or more stimulation parameters or information associated with one or more leads. In some embodiments, the trainer device may transmit a simulated first error information to the NP, wherein the first error information comprises an indication of a first error selected from a plurality of errors. In some embodiments, the trainer device may receive a response-information from the NP corresponding to a user input entered by a user to resolve the first error. In some embodiments, the trainer device may register within a local memory of the trainer device that the first error has been resolved. In some embodiments, the trainer device may have one or more retention pins configured to be secured to one or more open ports of the NP.

In some embodiments, the simulated neurostimulator information may include battery information of a simulated neurostimulator. In some embodiments the simulated neurostimulator information may include simulated current information related to a simulated stimulation program. That is, the simulated current information may include current information corresponding to a stimulation program that is currently ongoing. For example, the simulated current information may include values corresponding to one or more current stimulation parameters; an indication of whether stimulation is currently ON or OFF in the simulated stimulation program; an identification of one or more electrodes that are currently stimulating in the simulated stimulation program; an identification of one or more leads that are currently stimulating in the simulated stimulation program; an identification of one or more electrodes that are configured to be enabled in the simulated stimulation program; an identification of one or more leads that are configured to be enabled in the simulated stimulation program; and/or impedance information indicating a measured impedance. In some embodiments, the simulated neurostimulator information may include treatment data about a simulated treatment history of a simulated patient.

In some embodiments, the trainer device may access a data store of the trainer device, wherein the data store comprises a plurality of errors. The trainer device may select the first error from the plurality of errors. The plurality of errors may be maintained in a predetermined order. The first error may be selected based on this predetermined order. Alternatively, the first error may be selected at random from the plurality of errors. In some embodiments, the plurality of errors may include: a low-battery condition indicating that a battery of the pulse generator is approaching a critically low level; a low-battery condition indicating that a battery of the NP is approaching a critically low level; a disconnected- or faulty-lead condition indicating that a lead may be disconnected or otherwise faulty; an excessive-temperature condition indicating that the simulated neurostimulator is above a respective threshold temperature; and/or an excessive-temperature condition indicating that the NP is above a respective threshold temperature.

In some embodiments, the trainer device may transmit a simulated second error information to the NP. The second error information may include an indication of a second error selected from the plurality of errors. The plurality of errors may be maintained in a predetermined order. The second error may be next in sequence based on the predetermined order from the first error, or may be selected at random.

In some embodiments, the trainer device (or the NP) may receive a mode-selection input for cycling between or among two or more pulse-generator modes, wherein the pulse-generator modes comprise an IPG mode and an EPG mode. The trainer device (or the NP) may select a respective pulse-generator mode associated with the received mode-selection input.

In some embodiments, the trainer device may receive a user input requesting an error simulation. In response to receiving the user input, the trainer device may transmit an instruction to the NP to display a simulation of the first error. In some embodiments, the NP may directly receive the user input, in which case the NP may display the error simulation without further instruction from the trainer device. In some embodiments, the trainer device may turn on an error indicator associated with the trainer device that indicates that an error is being simulated. The trainer device may evaluate a response-information corresponding to one or more user inputs to determine if the corresponding one or more user inputs resolve the first error. In response to determining that the corresponding one or more user inputs resolve the first error, the training device may turn off the error indicator. In some embodiments, the evaluation may be performed by the NP, in which case the NP may send an error-resolution information to the trainer device indicating that the first error has been resolved (if the NP determines that the one or more inputs resolve the error).

In some embodiments, one or more indicators on an interface of the trainer device may be turned on or off. The indicators may include: a stimulation indicator that indicates whether or not the NP has successfully sent a command to the trainer device to turn on patient stimulation; one or more pulse-generator mode indicators that indicate whether the simulation is simulating an IPG or an EPG; or one or more error indicators that indicate whether an error is being simulated.

In some embodiments, the trainer device may include circuitry that includes a first circuitry for simulating the one or more neurostimulators, and a second circuitry for simulating placement of a lead. The second circuitry may include a fixed load that may provide a known resistance. The first circuitry and the second circuitry may be housed on separate circuit boards that are not electrically coupled to each other.

In some embodiments, the trainer device may include a foramen needle stimulation cable and a ground electrode cable, wherein the foramen needle stimulation cable is configured to be connected to a first port of the NP, and wherein the ground electrode cable is configured to be connected to a second port of the NP. The trainer device may receive, at the second circuitry, one or more electrical pulses from the NP, wherein the one or more electrical pulses form a completed circuit comprising the foramen needle stimulation cable, the ground electrode cable, and the fixed load of the second circuitry. The trainer device (or the NP) may measure an impedance of the completed circuit, wherein the impedance is associated with at least the fixed load. In embodiments where the trainer device measures the impedance, the trainer device may transmit, to the NP, information corresponding to the measured impedance.

In some embodiments, the trainer device may include a lead stimulation cable and a ground electrode cable, wherein the lead stimulation cable is configured to be connected to a first port of the NP, and wherein the ground electrode cable is configured to be connected to a second port of the NP. The trainer device may receive, at the second circuitry, one or more electrical pulses from the NP, wherein the one or more electrical pulses form a completed circuit comprising the lead stimulation cable, the ground electrode cable, and the fixed load of the second circuitry. The trainer device (or the NP) may measure an impedance of the completed circuit, wherein the impedance is associated with at least the fixed load. In embodiments where the trainer device measures the impedance, the trainer device may transmit, to the NP, information corresponding to the measured impedance.

In some embodiments, a connection may be established between a trainer device and the NP. Circuitry of the trainer device may transmit information identifying a plurality of potential neurostimulators. Circuitry of the trainer device may receive, from the NP, information corresponding to a user selection input by a user. The user selection input may specify a particular one of the plurality of potential neurostimulators. Circuitry of the trainer device may select the particular one of the plurality of neurostimulators for simulation.

Further areas of applicability of the present disclosure will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating various embodiments, are intended for purposes of illustration only and are not intended to necessarily limit the scope of the disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 schematically illustrates a nerve stimulation system, which includes a clinician programmer and a patient remote used in positioning and/or programming of both a trial neurostimulation system and a permanently implanted neurostimulation system, in accordance with aspects of the invention.

FIG. 2 illustrates an example of a fully implanted neurostimulation system in accordance with aspects of the invention.

FIG. 3 shows an example of a neurostimulation system having an implantable stimulation lead, an implantable pulse generator, and an external charging device, in accordance with aspects of the invention.

FIG. 4 illustrates an example of stimulation in a cycling mode, in which the duty cycle is the stimulation on time over the stimulation-on time plus the stimulation-off time.

FIG. 5 illustrates signal characteristics of a neurostimulation program, exhibiting a ramping feature.

FIG. 6 schematically illustrates a nerve stimulation system utilizing a control unit with a stimulation clip, a ground patch, two electromyography sensors, and ground patch sets connected during the operation of placing a trial or permanent neurostimulation system, in accordance with aspects of the invention.

FIG. 7 illustrates a schematic of a clinician programmer configuration.

FIG. 8 illustrates an example schematic of a printed circuit board assembly (PCBA) of a neurostimulator programmer including an example set of sensors disposed in example locations.

FIG. 9 illustrates an example embodiment of a trainer device showing the structure of a portable housing of the trainer device.

FIG. 10 illustrates an example diagram of the trainer device that is docked onto a NP.

FIG. 11 illustrates a schematic diagram of an example trainer device having separated first and second circuitry.

FIG. 12 illustrates an example method for simulating an error during a simulated neurostimulator programming session.

FIG. 13 illustrates an example method for simulating neurostimulation lead placement.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to neurostimulation treatment systems and associated devices, as well as methods of treatment, implantation/placement and configuration of such treatment systems. In particular, the invention relates to sacral nerve stimulation treatment systems configured to treat overactive bladder (“OAB”) and relieve symptoms of bladder related dysfunction. It will be appreciated however that the present invention may also be utilized for the treatment of pain or other indications, such as movement or affective disorders, as will be appreciated by one of skill in the art.

I. Neurostimulation Indications

Neurostimulation treatment systems, such as any of those described herein, can be used to treat a variety of ailments and associated symptoms, such as acute pain disorders, movement disorders, affective disorders, as well as bladder related dysfunction. Examples of pain disorders that may be treated by neurostimulation include failed back surgery syndrome, reflex sympathetic dystrophy or complex regional pain syndrome, causalgia, arachnoiditis, and peripheral neuropathy. Movement orders include muscle paralysis, tremor, dystonia and Parkinson's disease. Affective disorders include depressions, obsessive-compulsive disorder, cluster headache, Tourette syndrome and certain types of chronic pain. Bladder related dysfunctions include but are not limited to OAB, urge incontinence, urgency-frequency, and urinary retention. OAB can include urge incontinence and urgency-frequency alone or in combination. Urge incontinence is the involuntary loss or urine associated with a sudden, strong desire to void (urgency). Urgency-frequency is the frequent, often uncontrollable urges to urinate (urgency) that often result in voiding in very small amounts (frequency). Urinary retention is the inability to empty the bladder. Neurostimulation treatments can be configured to address a particular condition by effecting neurostimulation of targeted nerve tissues relating to the sensory and/or motor control associated with that condition or associated symptom.

In one aspect, the methods and systems described herein are particularly suited for treatment of urinary and fecal dysfunctions. These conditions have been historically under-recognized and significantly underserved by the medical community. OAB is one of the most common urinary dysfunctions. It is a complex condition characterized by the presence of bothersome urinary symptoms, including urgency, frequency, nocturia and urge incontinence. It is estimated that about 33 million Americans suffer from OAB. Of the adult population, about 30% of all men and 40% of all women live with OAB symptoms.

OAB symptoms can have a significant negative impact on the psychosocial functioning and the quality of life of patients. People with OAB often restrict activities and/or develop coping strategies. Furthermore, OAB imposes a significant financial burden on individuals, their families, and healthcare organizations. The prevalence of co-morbid conditions is also significantly higher for patients with OAB than in the general population. Co-morbidities may include falls and fractures, urinary tract infections, skin infections, vulvovaginitis, cardiovascular, and central nervous system pathologies. Chronic constipation, fecal incontinence, and overlapping chronic constipation occur more frequently in patients with OAB.

Conventional treatments of OAB generally include lifestyle modifications as a first course of action. Lifestyle modifications include eliminating bladder irritants (such as caffeine) from the diet, managing fluid intake, reducing weight, stopping smoking, and managing bowel regularity. Behavioral modifications include changing voiding habits (such as bladder training and delayed voiding), training pelvic floor muscles to improve strength and control of urethral sphincter, biofeedback and techniques for urge suppression. Medications are considered a second-line treatment for OAB. These include anti-cholinergic medications (oral, transdermal patch, and gel) and oral beta-3 adrenergic agonists. However, anti-cholinergics are frequently associated with bothersome, systemic side effects including dry mouth, constipation, urinary retention, blurred vision, somnolence, and confusion. Studies have found that more than 50% of patients stop using anti-cholinergic medications within 90 days due to a lack of benefit, adverse events, or cost.

When these approaches are unsuccessful, third-line treatment options suggested by the American Urological Association include intradetrusor (bladder smooth muscle) injections of Botulinum Toxin (BoNT-A), Percutaneous Tibial Nerve Stimulation (PTNS) and Sacral Nerve Stimulation (SNM). BoNT-A (Botox®) is administered via a series of intradetrusor injections under cystoscopic guidance, but repeat injections of Botox are generally required every 4 to 12 months to maintain effect and Botox may undesirably result in urinary retention. A number or randomized controlled studies have shown some efficacy of BoNT-A in OAB patients, but long-term safety and effectiveness of BoNT-A for OAB is largely unknown.

Alternative treatment methods, typically considered when the above approaches prove ineffective, is neurostimulation of nerves relating to the urinary system. Such neurostimulation methods include PTNS and SNM. PTNS therapy consists of weekly, 30-minute sessions over a period of 12 weeks, each session using electrical stimulation that is delivered from a hand-held stimulator to the sacral plexus via the tibial nerve. For patients who respond well and continue treatment, ongoing sessions, typically every 3-4 weeks, are needed to maintain symptom reduction. There is potential for declining efficacy if patients fail to adhere to the treatment schedule. Efficacy of PTNS has been demonstrated in a few randomized-controlled studies, however, long-term safety and effectiveness of PTNS is relatively unknown at this time.

II. Sacral Neuromodulation

SNM is an established therapy that provides a safe, effective, reversible, and long-lasting treatment option for the management of urge incontinence, urgency-frequency, and non-obstructive urinary retention. SNM therapy involves the use of mild electrical pulses to stimulate the sacral nerves located in the lower back. Electrodes are placed next to a sacral nerve, usually at the S3 level, by inserting the electrode leads into the corresponding foramen of the sacrum. The electrodes are inserted subcutaneously and are subsequently attached to an implantable pulse generator (IPG). The safety and effectiveness of SNM for the treatment of OAB, including durability at five years for both urge incontinence and urgency-frequency patients, is supported by multiple studies and is well-documented. SNM has also been approved to treat chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments.

A. Implantation of Sacral Neuromodulation System

Currently, SNM qualification has a trial phase, and is followed if successful by a permanent implant. The trial phase is a test stimulation period where the patient is allowed to evaluate whether the therapy is effective. Typically, there are two techniques that are utilized to perform the test stimulation. The first is an office-based procedure termed percutaneous nerve evaluation and the other is a staged trial.

In percutaneous nerve evaluation, a foramen needle is typically used first to identify the optimal stimulation location, usually at the S3 level, and to evaluate the integrity of the sacral nerves. Motor and sensory responses are used to verify correct needle placement, as described in Table 1 below. A temporary stimulation lead (a unipolar electrode) is then placed near the sacral nerve under local anesthesia. This procedure can be performed in an office setting without fluoroscopy. The temporary lead is then connected to an external pulse generator (EPG) taped onto the skin of the patient during the trial phase. The stimulation level can be adjusted to provide an optimal comfort level for the particular patient. The patient will monitor his or her voiding for 3 to 7 days to see if there is any symptom improvement. The advantage of percutaneous nerve evaluation is that it is an incision free procedure that can be performed in the physician's office using local anesthesia. The disadvantage is that the temporary lead is not securely anchored in place and has the propensity to migrate away from the nerve with physical activity and thereby cause failure of the therapy. If a patient fails this trial test, the physician may still recommend the staged trial as described below. If the percutaneous nerve evaluation trial is positive, the temporary trial lead is removed and a permanent quadri-polar tined lead is implanted along with an IPG under general anesthesia.

A staged trial involves the implantation of the permanent quadri-polar tined stimulation lead into the patient from the start. It also requires the use of a foramen needle to identify the nerve and optimal stimulation location. The lead is implanted near the S3 sacral nerve and is connected to an EPG via a lead extension. This procedure is performed under fluoroscopic guidance in an operating room and under local or general anesthesia. The EPG is adjusted to provide an optimal comfort level for the patient and the patient monitors his or her voiding for up to two weeks. If the patient obtains meaningful symptom improvement, he or she is considered a suitable candidate for permanent implantation of the IPG under general anesthesia, typically in the upper buttock area, as shown in FIG. 2.

In regard to measuring outcomes for SNM treatment of voiding dysfunction, the voiding dysfunction indications (for example, urge incontinence, urgency-frequency, and non-obstructive urinary retention) are evaluated by unique primary voiding diary variables. The therapy outcomes are measured using these same variables. SNM therapy is considered successful if a minimum of 50% improvement occurs in any of primary voiding diary variables compared with the baseline. For urge incontinence patients, these voiding diary variables may include: number of leaking episodes per day, number of heavy leaking episodes per day, and number of pads used per day. For patients with urgency-frequency, primary voiding diary variables may include: number of voids per day, volume voided per void and degree of urgency experienced before each void. For patients with retention, primary voiding diary variables may include: catheterized volume per catheterization and number of catheterizations per day.

The mechanism of action of SNM is multifactorial and impacts the neuro-axis at several different levels. In patients with OAB, it is believed that pudendal afferents can activate the inhibitory reflexes that promote bladder storage by inhibiting the afferent limb of an abnormal voiding reflex. This blocks input to the pontine micturition center, thereby restricting involuntary detrusor contractions without interfering with normal voiding patterns. For patients with urinary retention, SNM is believed to activate the pudendal nerve afferents originating from the pelvic organs into the spinal cord. At the level of the spinal cord, pudendal afferents may turn on voiding reflexes by suppressing exaggerated guarding reflexes, thus relieving symptoms of patients with urinary retention so normal voiding can be facilitated. In patients with fecal incontinence, it is hypothesized that SNM stimulates pudendal afferent somatic fibers that inhibit colonic propulsive activity and activates the internal anal sphincter, which in turn improves the symptoms of fecal incontinence patients. The present invention relates to a system adapted to deliver neurostimulation to targeted nerve tissues in a manner that disrupt, inhibit, or prevent neural activity in the targeted nerve tissues so as to provide therapeutic effect in treatment of OAB or bladder related dysfunction. In one aspect, the system is adapted to provide therapeutic effect by neurostimulation without inducing motor control of the muscles associated with OAB or bladder related dysfunction by the delivered neurostimulation. In another aspect, the system is adapted to provide such therapeutic effect by delivery of sub-threshold neurostimulation below a threshold that induces paresthesia and/or neuromuscular response or to allow adjustment of neurostimulation to delivery therapy at sub-threshold levels.

B. Positioning Neurostimulation Leads with EMG

Placement of the neurostimulation lead may require localization of the targeted nerve and subsequent positioning of the neurostimulation lead at the target location. Various ancillary components are used for localization of the target nerve and subsequent implantation of the lead and IPG. Such components may include a foramen needle and a stylet, a directional guide, dilator and an introducer sheath, straight or curved tip stylet (inserted in tined leads), tunneling tools (a bendable tunneling rod with sharp tip on one end and a handle on the other with a transparent tubing over the tunneling rod) and often an over-the-shelf torque wrench. The foramen needle and stylet may be used for locating the correct sacral foramen for implant lead and subsequent acute stimulation testing. The physician may locate the targeted nerve by inserting a foramen needle and energizing a portion of needle until a neuromuscular response is observed that is indicative of neurostimulation in the target area (see Table 1 above). After the target nerve is successfully located, the direction guide, introducer and dilator may be used to prepare a path along which the lead can be implanted. The directional guide is a metal rod that holds the position in the sacral foramen determined with the foramen needle for subsequent placement of the introducer sheath and dilator. The introducer sheath and dilator is a tool that increases the diameter of the hole through the foramen to allow introduction of the permanent lead. The lead stylet is a stiff wire that is inserted into the lead to increase its stiffness during lead placement and may be configured with a straight or curved tip. The torque wrench is a small wrench used to tighten the set screw that locks the lead into the IPG. The tunneling tool is a stiff, sharp device that creates a subcutaneous tunnel, allowing the lead to be placed along a path under the skin. While such approaches have sufficed for many conventional treatments, such approaches often lack resolution and may result in sub-optimal lead placement, which may unnecessarily complicate subsequent programming and result in unfavorable patient outcomes. Thus, an approach that provides more accurate and robust neural localization while improving ease of use by the physician and the patient.

Neurostimulation relies on consistently delivering therapeutic stimulation from a pulse generator, via one or more neurostimulation electrodes, to particular nerves or targeted regions. The neurostimulation electrodes are provided on a distal end of an implantable lead that can be advanced through a tunnel formed in patient tissue. Implantable neurostimulation systems provide patients with great freedom and mobility, but it may be easier to adjust the neurostimulation electrodes of such systems before they are surgically implanted. It is desirable for the physician to confirm that the patient has desired motor and/or sensory responses before implanting an IPG. For at least some treatments (including treatments of at least some forms of urinary and/or fecal dysfunction), demonstrating appropriate motor responses may be highly beneficial for accurate and objective lead placement while the sensory response may not be required or not available (for example, patient is under general anesthesia).

Placement and calibration of the neurostimulation electrodes and implantable leads sufficiently close to specific nerves can be beneficial for the efficacy of treatment. Accordingly, aspects and embodiments of the present disclosure are directed to aiding and refining the accuracy and precision of neurostimulation electrode placement. Further, aspects and embodiments of the present disclosure are directed to aiding and refining protocols for setting therapeutic treatment signal parameters for a stimulation program implemented through implanted neurostimulation electrodes.

Prior to implantation of the permanent device, patients may undergo an initial testing phase to estimate potential response to treatment. As discussed above, percutaneous nerve evaluation may be done under local anesthesia, using a test needle to identify the appropriate sacral nerve(s) according to a subjective sensory response by the patient. Other testing procedures can involve a two-stage surgical procedure, where a quadri-polar tined lead is implanted for a testing phase to determine if patients show a sufficient reduction in symptom frequency, and if appropriate, proceeding to the permanent surgical implantation of a neuromodulation device. For testing phases and permanent implantation, determining the location of lead placement can be dependent on subjective qualitative analysis by either or both of a patient or a physician.

In exemplary embodiments, determination of whether or not an implantable lead and neurostimulation electrode is located in a desired or correct location can be accomplished through use of electromyography (“EMG”), also known as surface electromyography. EMG, is a technique that uses an EMG system or module to evaluate and record electrical activity produced by muscles, producing a record called an electromyogram. EMG detects the electrical potential generated by muscle cells when those cells are electrically or neurologically activated. The signals can be analyzed to detect activation level or recruitment order. EMG can be performed through the skin surface of a patient, intramuscularly or through electrodes disposed within a patient near target muscles, or using a combination of external and internal structures. When a muscle or nerve is stimulated by an electrode, EMG can be used to determine if the related muscle is activated, (i.e. whether the muscle fully contracts, partially contracts, or does not contract) in response to the stimulus. Accordingly, the degree of activation of a muscle can indicate whether an implantable lead or neurostimulation electrode is located in the desired or correct location on a patient. Further, the degree of activation of a muscle can indicate whether a neurostimulation electrode is providing a stimulus of sufficient strength, amplitude, frequency, or duration to affect a treatment regimen on a patient. Thus, use of EMG provides an objective and quantitative means by which to standardize placement of implantable leads and neurostimulation electrodes, reducing the subjective assessment of patient sensory responses.

In some approaches, positional titration procedures may optionally be based in part on a paresthesia or pain-based subjective response from a patient. In contrast, EMG triggers a measureable and discrete muscular reaction. As the efficacy of treatment often relies on precise placement of the neurostimulation electrodes at target tissue locations and the consistent, repeatable delivery of neurostimulation therapy, using an objective EMG measurement can substantially improve the utility and success of SNM treatment. The measurable muscular reaction can be a partial or a complete muscular contraction, including a response below the triggering of an observable motor response, such as those shown in Table 1, depending on the stimulation of the target muscle. In addition, by utilizing a trial system that allows the neurostimulation lead to remain implanted for use in the permanently implanted system, the efficacy and outcome of the permanently implanted system is more consistent with the results of the trial period, which moreover leads to improved patient outcomes.

C. Example Embodiments of Neurostimulation Systems

FIG. 1 schematically illustrates an exemplary nerve stimulation system, which includes both a trial neurostimulation system 200 and a permanently implanted neurostimulation system 100, in accordance with aspects of the invention. The EPG 80 and IPG 10 are each compatible with and wirelessly communicate with a clinician programmer 60 and a patient remote 70, which are used in positioning and/or programming the trial neurostimulation system 200 and/or permanently implanted system 100 after a successful trial. As discussed above, the clinician programmer can include specialized software, specialized hardware, and/or both, to aid in lead placement, programming, re-programming, stimulation control, and/or parameter setting. In addition, each of the IPG and the EPG allows the patient at least some control over stimulation (for example, initiating a pre-set program, increasing or decreasing stimulation), and/or to monitor battery status with the patient remote. This approach also allows for an almost seamless transition between the trial system and the permanent system.

In one aspect, the clinician programmer 60 is used by a physician to adjust the settings of the EPG and/or IPG while the lead is implanted within the patient. The clinician programmer can be a tablet computer used by the clinician to program the IPG, or to control the EPG during the trial period. The clinician programmer can also include capability to record stimulation-induced electromyograms to facilitate lead placement and programming. The patient remote 70 can allow the patient to turn the stimulation on or off, or to vary stimulation from the IPG while implanted, or from the EPG during the trial phase.

In another aspect, the clinician programmer 60 has a control unit which can include a microprocessor and specialized computer-code instructions for implementing methods and systems for use by a physician in deploying the treatment system and setting up treatment parameters. The clinician programmer generally includes a user interface which can be a graphical user interface, an EMG module, electrical contacts such as an EMG input that can couple to an EMG output stimulation cable, an EMG stimulation signal generator, and a stimulation power source. The stimulation cable can further be configured to couple to any or all of an access device (for example, a foramen needle), a treatment lead of the system, or the like. The EMG input may be configured to be coupled with one or more sensory patch electrode(s) for attachment to the skin of the patient adjacent a muscle (for example, a muscle enervated by a target nerve). Other connectors of the clinician programmer may be configured for coupling with an electrical ground or ground patch, an electrical pulse generator (for example, an EPG or an IPG), or the like. As noted above, the clinician programmer can include a module with hardware and computer-code to execute EMG analysis, where the module can be a component of the control unit microprocessor, a pre-processing unit coupled to or in-line with the stimulation and/or sensory cables, or the like.

In some aspects, the clinician programmer is configured to operate in combination with an EPG when placing leads in a patient body. The clinician programmer can be electronically coupled to the EPG during test simulation through a specialized cable set. The test simulation cable set can connect the clinician programmer device to the EPG and allow the clinician programmer to configure, modify, or otherwise program the electrodes on the leads connected to the EPG.

In other aspects, the clinician programmer 60 allows the clinician to read the impedance of each electrode contact whenever the lead is connected to an EPG, an IPG or a clinician programmer 60 to ensure reliable connection is made and the lead is intact. This may be used as an initial step in both positioning the lead and in programming the leads to ensure the electrodes are properly functioning. The clinician programmer 60 is also able to save and display previous (for example, up to the last four) programs that were used by a patient to help facilitate re-programming. In some embodiments, the clinician programmer 60 further includes a USB port for saving reports to a USB drive and a charging port. The clinician programmer 60 is configured to operate in combination with an EPG when placing leads in a patient body as well with the IPG during programming. The clinician programmer 60 can be electronically coupled to the EPG during test simulation through a specialized cable set or through wireless communication, thereby allowing the clinician programmer 60 to configure, modify, or otherwise program the electrodes on the leads connected to the EPG. The clinician programmer 60 may also include physical on/off buttons to turn the clinician programmer 60 on and off and/or to turn stimulation on and off.

The electrical pulses generated by the EPG and IPG are delivered to one or more targeted nerves via one or more neurostimulation electrodes at or near a distal end of each of one or more leads. The leads can have a variety of shapes, can be a variety of sizes, and can be made from a variety of materials, which size, shape, and materials can be tailored to the specific treatment application. While in this embodiment, the lead is of a suitable size and length to extend from the IPG and through one of the foramen of the sacrum to a targeted sacral nerve, in various other applications, the leads may be, for example, implanted in a peripheral portion of the patient's body, such as in the arms or legs, and can be configured to deliver electrical pulses to the peripheral nerve such as may be used to relieve chronic pain. It is appreciated that the leads and/or the stimulation programs may vary according to the nerves being targeted.

FIG. 2 schematically illustrates an example of a fully implanted neurostimulation system 100 adapted for sacral nerve stimulation. Neurostimulation system 100 includes an IPG implanted in a lower back region and connected to a neurostimulation lead extending through the S3 foramen for stimulation of the S3 sacral nerve. The lead is anchored by a tined anchor portion 30 that maintains a position of a set of neurostimulation electrodes 40 along the targeted nerve, which in this example, is the anterior sacral nerve root S3 which enervates the bladder so as to provide therapy for various bladder related dysfunctions. While this embodiment is adapted for sacral nerve stimulation, it is appreciated that similar systems can be used in treating patients with, for example, chronic, severe, refractory neuropathic pain originating from peripheral nerves or various urinary dysfunctions or still further other indications. Implantable neurostimulation systems can be used to either stimulate a target peripheral nerve or the posterior epidural space of the spine.

Properties of the electrical pulses can be controlled via a controller of the implanted pulse generator. In some embodiments, these properties can include, for example, the frequency, strength, pattern, duration, or other aspects of the electrical pulses. These properties can include, for example, a voltage, a current, or the like. This control of the electrical pulses can include the creation of one or more electrical pulse programs, plans, or patterns, and in some embodiments, this can include the selection of one or more pre-existing electrical pulse programs, plans, or patterns. In the embodiment depicted in FIG. 2, the implantable neurostimulation system 100 includes a controller in the IPG having one or more pulse programs, plans, or patterns that may be pre-programmed or created as discussed above. In some embodiments, these same properties associated with the IPG may be used in an EPG of a partly implanted trial system used before implantation of the permanent neurostimulation system 100.

In one aspect, the EPG unit is wirelessly controlled by a patient remote and/or the clinician programmer in a similar or identical manner as the IPG of a permanently implanted system. The physician or patient may alter treatment provided by the EPG through use of such portable remotes or programmers and the treatments delivered are recorded on a memory of the programmer for use in determining a treatment suitable for use in a permanently implanted system. The clinician programmer can be used in lead placement, programming and/or stimulation control in each of the trial and permanent nerve stimulation systems. In addition, each nerve stimulation system allows the patient to control stimulation or monitor battery status with the patient remote. This configuration is advantageous as it allows for an almost seamless transition between the trial system and the permanent system. From the patient's viewpoint, the systems will operate in the same manner and be controlled in the same manner, such that the patient's subjective experience in using the trial system more closely matches what would be experienced in using the permanently implanted system. Thus, this configuration reduces any uncertainties the patient may have as to how the system will operate and be controlled such that the patient will be more likely to convert a trial system to a permanent system.

FIG. 3 illustrates an example neurostimulation system 100 that is fully implantable and adapted for sacral nerve stimulation treatment. The implantable system 100 includes an IPG 10 that is coupled to a neurostimulation lead 20 that includes a group of neurostimulation electrodes 40 at a distal end of the lead. The lead includes a lead anchor portion 30 with a series of tines extending radially outward so as to anchor the lead and maintain a position of the neurostimulation lead 20 after implantation. The lead 20 may further include one or more radiopaque markers 25 to assist in locating and positioning the lead using visualization techniques such as fluoroscopy. In some embodiments, the IPG provides monopolar or bipolar electrical pulses that are delivered to the targeted nerves through one or more neurostimulation electrodes, typically four electrodes. In sacral nerve stimulation, the lead is typically implanted through the S3 foramen as described herein.

In one aspect, the IPG is rechargeable wirelessly through conductive coupling by use of a charging device 50 (CD), which is a portable device powered by a rechargeable battery to allow patient mobility while charging. The CD is used for transcutaneous charging of the IPG through RF induction. The CD can either be either patched to the patient's skin using an adhesive or can be held in place using a belt 53 or by an adhesive patch 52, such as shown in the schematic of FIG. 6. The CD may be charged by plugging the CD directly into an outlet or by placing the CD in a charging dock or station 51 that connects to an AC wall outlet or other power source.

The system may further include a patient remote 70 and clinician programmer 60, each configured to wirelessly communicate with the implanted IPG, or with the EPG during a trial, as shown in the schematic of the nerve stimulation system in FIG. 6. The clinician programmer 60 may be a tablet computer used by the clinician to program the IPG and the EPG. The device also has the capability to record stimulation-induced electromyograms (EMGs) to facilitate lead placement, programming, and/or re-programming. The patient remote may be a battery-operated, portable device that utilizes radio-frequency (RF) signals to communicate with the EPG and IPG and allows the patient to adjust the stimulation levels, check the status of the IPG battery level, and/or to turn the stimulation on or off.

One or more of the pulse generators can include a processor and/or memory adapted to provide instructions to and receive information from the other components of the implantable neurostimulation system. The processor can include a microprocessor, such as a commercially available microprocessor from Intel® or Advanced Micro Devices, Inc.®, or the like. An IPG may include an energy storage feature, such as one or more capacitors, and typically includes a wireless charging unit.

One or more properties of the electrical pulses can be controlled via a controller of the IPG or EPG. In some embodiments, these properties can include, for example, the frequency, strength, pattern, duration, or other aspects of the timing and magnitude of the electrical pulses. These properties can further include, for example, a voltage, a current, or the like. This control of the electrical pulses can include the creation of one or more electrical pulse programs, plans, or patterns, and in some embodiments, this can include the selection of one or more pre-existing electrical pulse programs, plans, or patterns. In one aspect, the IPG 10 includes a controller having one or more pulse programs, plans, or patterns that may be created and/or pre-programmed. In some embodiments, the IPG can be programmed to vary stimulation parameters including pulse amplitude in a range from 0 mA to 10 mA, pulse width in a range from 50 μs to 500 μs, pulse frequency in a range from 5 Hz to 250 Hz, stimulation modes (for example, continuous or cycling), and electrode configuration (for example, anode, cathode, or off), to achieve the optimal therapeutic outcome specific to the patient. In particular, this allows for an optimal setting to be determined for each patient even though each parameter may vary from person to person.

FIG. 4 shows an example of stimulation in a cycling mode, in which the duty cycle is the stimulation on time over the stimulation-on time plus the stimulation-off time. In some embodiments, the IPG, as well as the EPG, may be configured for example with two stimulation modes: continuous mode and cycling mode, such as shown in FIG. 4. The cycling mode may save energy in comparison to the continuous mode, thereby extending the recharge interval of the battery and lifetime of the device. The cycling mode may also help reduce the risk of neural adaptation for some patients. Neural adaptation is a change over time in the responsiveness of the neural system to a constant stimulus. Thus, cycling mode may also mitigate neural adaptation so to provide longer-term therapeutic benefit.

In some embodiments, the IPG/EPG is configured with a ramping feature, such as shown in the example of FIG. 5. In these embodiments, the stimulation signal is ramped up and/or down between the stimulation-on and stimulation-off levels. This feature helps reduce the sudden “jolting” or “shocking” sensation that some patients might experience when the stimulation is initially turned on or at the cycle-on phase during the cycling mode. This feature is particularly of benefit for patients who need relative high stimulation settings and/or for patients who are sensitive to electrical stimulation.

FIG. 6 shows a setup for a test stimulation and EMG sensing using a clinician programmer 60. As discussed above, the clinician programmer 60 is a tablet computer with software that runs on a standard operating system. The clinician programmer 60 includes a communication module, a stimulation module and an EMG sensing module. The communication module communicates with the IPG and/or EPG in the medical implant communication service frequency band for programming the IPG and/or EPG.

In order to confirm correct lead placement, it is desirable for the physician to confirm that the patient has both adequate motor and sensory responses before transitioning the patient into the staged trial phase or implanting the permanent IPG. However, sensory response is a subjective evaluation and may not always be available, such as when the patient is under general anesthesia. Experiments have shown that demonstrating appropriate motor responses is advantageous for accurate placement, even if sensory responses are available. As discussed above, EMG is a tool which records electrical activity of skeletal muscles. This sensing feature provides an objective criterion for the clinician to determine if the sacral nerve stimulation results in adequate motor response rather than relying solely on subjective sensory criteria. EMG can be used not only to verify optimal lead position during lead placement, but also to provide a standardized and more accurate approach to determine electrode thresholds, which in turn provides quantitative information supporting electrode selection for programming. Using EMG to verify activation of motor responses can further improve the lead placement performance of less experienced operators and allow such physicians to perform lead placement with confidence and greater accuracy.

In one aspect, the system is configured to have EMG sensing capability during re-programming, which can be particularly valuable. Stimulation levels during re-programming are typically low to avoid patient discomfort which often results in difficult generation of motor responses. Involuntary muscle movement while the patient is awake may also cause noise that is difficult for the physician to differentiate. In contrast to conventional approaches, EMG allows the clinician to detect motor responses at very low stimulation levels (for example, sub-threshold), and help them distinguish a motor response originated by sacral nerve stimulation from involuntary muscle movement.

Referring to FIG. 6, several cable sets are connected to the CP. The stimulation cable set consists of one stimulation mini-clip 3 and one ground patch 5. It is used with a foramen needle 1 to locate the sacral nerve and verify the integrity of the nerve via test stimulation. Another stimulation cable set with four stimulation channels 2 is used to verify the lead position with a tined stimulation lead 20 during the staged trial. Both cable sets are sterilizable as they will be in the sterile field. A total of five over-the-shelf sensing electrode patches 4 (for example, two sensing electrode pairs for each sensing spot and one common ground patch) are provided for EMG sensing at two different muscle groups (for example, perineal musculature and big toe) simultaneously during the lead placement procedure. This provides the clinician with a convenient all-in-one setup via the EMG integrated clinician programmer. Typically, only one electrode set (for example, two sensing electrodes and one ground patch) is needed for detecting an EMG signal on the big toe during an initial electrode configuration and/or re-programming session. Typically, these over-the-shelf EMG electrodes are also provided sterile though not all cables are required to be connected to the sterile field. The clinician programmer 60 may allow the clinician to read the impedance of each electrode contact whenever the lead is connected to an EPG, an IPG or a clinician programmer to ensure reliable connection is made and the lead is intact. The clinician programmer 60 is also able to save and display previous (for example, up to the last four) programs that were used by a patient to help facilitate re-programming. In some embodiments, the clinician programmer 60 further includes a USB port for saving reports to a USB drive and a charging port. The clinician programmer may also include physical on/off buttons to turn the clinician programmer on and off and/or to turn stimulation on and off.

FIG. 7 schematically illustrates a block diagram of the configuration of the CP 60 and associated interfaces and internal components. As described above, CP 60 is typically a tablet computer with software that runs on a standard operating system. The CP 60 includes a communication module, a stimulation module and an EMG sensing module. The communication module communicates with the IPG and/or EPG in the medical implant communication service frequency band for programming the IPG and/or EPG. While this configuration reflects a portable user interface display device, such as a tablet computer, it is appreciated that the CP may be incorporated into various other types of computing devices, such as a laptop, desktop computer, or a standalone terminal for use in a medical facility.

FIG. 8 illustrates an example schematic of a printed circuit board assembly (PCBA) of a neurostimulator programmer including an example set of sensors disposed in example locations. In some embodiments, the PCBA may include a CPU sensor 815 that may be at or near a CPU 810. The CPU sensor 815 may be located such that it is suited for detecting heat generated by the CPU 810. In some embodiments, the PCBA may include a display sensor 825 that may be at or near one or more backlight components (for example, LCD backlight components 820) of the neurostimulator programmer. The backlight components may include, for example, an inverter and/or LEDs of the backlight. The display sensor 825 may be located such that it is suited for detecting heat generated by the display. In some embodiments, the PCBA may include a charger sensor 835 that may be at or near a charging module (for example, the battery charger chip 830). The charger sensor 835 may be located such that it is suited for detecting heat generated by the charging module as it, for example, steps down voltage, as described elsewhere herein. In some embodiments, the PCBA may include a battery sensor 845 that may be at or near a battery pack 840. The battery pack 840 may include one battery or several batteries that may be coupled together. The battery sensor 845 may be located such that it is suited for detecting heat generated by the charging or discharging of the battery pack 840 or components thereof. Although FIG. 8 illustrates a configuration that includes four different types of sensors (the CPU sensor 815, the display sensor 825, the charger sensor 835, and the battery sensor 845), this disclosure contemplates any number or combination of these types of sensors and/or any other suitable types of sensors. Moreover, although FIG. 8 illustrates only one sensor of each type (for example, only one battery sensor 845, only one display sensor 825) this disclosure contemplates that any suitable number of such sensors may be incorporated into the PCBA. For example, in a case where the battery pack includes four different batteries, there may be a battery sensor 845 adjacent to each of the four different batteries.

III. Trainer for a Neurostimulator Programmer (NP)

In some embodiments, a neurostimulator programmer (NP) may be provided for programming a neurostimulator. The NP may be, for example, the clinician programmer 60, which may be used by a clinician or another suitable operator to program or adjust parameters of one or more neurostimulators. In some embodiments, the programmer may be a patient programmer. The NP may be used to communicate wirelessly with and control either an EPG or an IPG. Alternatively or additionally, the programmer may communicate over a wired connection with the EPG or IPG. Programming a neurostimulator and ensuring proper placement of leads is a complex task that may require extensive hands-on training on the part of a clinician or an instructor (such as an employee of the manufacturer, who may be commissioned to train the clinician). Simply reading a manual for viewing training videos may not provide adequate training. For example, programming a neurostimulator in the real world may involve dealing in real-time with a series of faults or errors that may occur during implantation or programming. As such, a trainer device that may realistically simulate tasks related to the programming of an EPG or IPG is provided for training a user, who may be, for example, a clinician or an instructor. The trainer device may also simulate tasks related to the implantation of leads. For example, the trainer device may simulate one or more checks that may need to be performed to ensure that proper lead placement has occurred. The trainer device may offer an intuitive, easy-to-use means of training users, providing a stimulation that provides conditions very close to what the user would expect in real-world situations. Furthermore, the trainer device may offer an affordable means of training. Neurostimulator devices such as EPGs and IPGs are by their nature expensive. As such, training users directly with these devices (for example, by connecting the NP to an EPG) is essentially infeasible in many cases, particularly when there are a large number of users to be trained. The trainer device may be manufactured relatively cheaply with simpler components, and may thus offer a cheaper alternative to using expensive EPGs and IPGs for training purposes. The resulting low-cost training system may be sufficiently available such that a larger number of clinicians or instructors may be able to have access to practical training for longer periods of time. Although the disclosure focuses on training clinicians and instructors of clinicians, the disclosure contemplates training devices such as the ones disclosed herein for training patients. For example, the NP may be a patient remote 70.

FIG. 9 illustrates an example embodiment of a trainer device 900 showing the structure of a portable housing 902 of the trainer device 900. In some embodiments, the portable housing 902 may have one or more exterior surfaces including one or more interface surfaces. For example, it may have an interface surface on a top side of the exterior surface (this top side is displayed in the example embodiment illustrated in FIG. 9). This interface surface may include one or more switches. For example, the interface surface may include the switch 920, which may be an ON/OFF button that turns the device on or off when pressed or held (for example, turning the device on when pressed and turning the device of when held down for a threshold period of time). Additionally or alternatively, the switch 920 may, for example, be used to cycle between different pulse-generator modes. For example, while the trainer device 900 is on, pressing the switch 920 may cause the trainer device 902 to cycle between an EPG mode and an IPG mode. In some embodiments, the interface surface may include one or more indicators, which may be for example, LEDs or some other suitable light source. For example, the interface surface may include the stimulation indicator 910, which may be a flashing LED that turns on when the NP successfully sends a command to the trainer device 900 to turn on patient stimulation. The LED may turn off when NP sends a command to turn off emulation. As another example, the interface surface may include the IPG indicator 916 which may turn on when the trainer device is turned on and in IPG mode. As another example, the interface surface may include the EPG indicator 914, which may turn on when the trainer device is turned on and in EPG mode. As another example, the interface surface may include a single mode indicator that indicates a current pulse-generator mode (for example, a single indicator that indicates whether the trainer device is in IPG mode or EPG mode). In some embodiments, the interface surface may include an element that is both a switch and an indicator. For example, the interface surface may include the error element 912, which may be an indicator that turns on when a fault status or error is being simulated, as well as a button that may be used to cause the simulation of an error. In this example, the trainer device 900 may send an instruction to the NP to display a simulation of a fault or error. For example, the user may press the error element 912, which may cause the stimulation of a preprogrammed fault. The user may take an appropriate action on the NP to clear the fault or error. If the user action is deemed appropriate, the indicator of the error element 912 may be turned off. In some embodiments, the interface surface may include an element for switching between different simulated stimulation modes (for example, continuous mode and cycling mode).

In some embodiments, the trainer device 900 may be configured to be docked onto a NP. FIG. 10 illustrates an example diagram of the trainer device 900 that is docked onto a NP 1010. For example, as shown in FIG. 10, the portable housing 902 of the trainer device 900 may be shaped such that it conforms to a curvature of the NP 1010 (for example, a clinician programmer 60). In some embodiments, the trainer device 900 may include one or more retention pins 904 (for example, as shown in FIG. 9) which may be configured to be fitted into one or more open ports of the NP 1010, or otherwise affixed to the NP 1010, to assist in securing the trainer device 900 to the NP 1010.

In some embodiments, the trainer device 900 may be used to provide a simulation of a neurostimulator programming session. In some embodiments, the user may engage with the simulation via an interface surface of the trainer device 900 and/or a display. The display may be, for example, a display associated with the NP or a display of the trainer device 900 (for example, one that is coupled to the trainer device 900). The display may present a variety of information that may be available to a clinician while programming or monitoring an IPG or EPG in a real-world situation. For example, the display may present a simulated current battery information of a simulated IPG or EPG (for example, voltage, capacity, etc.), status information related to a simulated stimulation program (for example, whether stimulation is on or off, stimulation parameters, an identification of the electrodes and/or leads that are currently stimulating as part of the simulation, an identification of the electrodes and/or leads configured to be enabled in the simulated stimulation program), or impedance information (for example, a simulated impedance provided by tissue around a lead in a real-world situation). The display may also provide information to the user that may require a user action. For example, the display may present one or more simulated faults or errors that may need to be solved by an appropriate action by the user.

In some embodiments, the trainer device 900 may be coupled to a NP. In some embodiments, the NP may be wirelessly coupled (for example, using a wireless network, Bluetooth, near field communication, far field communication) directly or indirectly to the NP. In some embodiments, the user may be able to initiate communication between the trainer device 900 and the NP. For example, the user may be able to “discover” the trainer device 900 on the NP when it is in range (for example, the user may receive a prompt on a display of the NP that the trainer device 900 is in range) and turned on, and may be able to initiate a connection to the trainer device 900 using the NP. As another example, the user may be able to actuate a switch on the trainer device 900, which may cause the trainer device 900 to automatically couple to the NP if it is in range, or send a connection prompt to the NP which may be accepted by the user. The trainer device and the NP may negotiate and establish a connection by any suitable protocols. In other embodiments, the NP may be coupled to the NP via a wired connection.

In some embodiments, the trainer device 900 may transmit simulated neurostimulator information to the NP as part of a simulation of a particular neurostimulator. In some embodiments, the simulated neurostimulator information may include battery information of the simulated neurostimulator. In some embodiments, the simulated neurostimulator information may include one or more stimulation parameters. In some embodiments, the simulated neurostimulator information may include information associated with one or more leads. In some embodiments the simulated neurostimulator information may include simulated current information related to a simulated stimulation program. That is, the simulated current information may include current information corresponding to a stimulation program that is currently ongoing. For example, the simulated current information may include values corresponding to one or more current stimulation parameters; an indication of whether stimulation is currently ON or OFF in the simulated stimulation program; an identification of one or more electrodes that are currently stimulating in the simulated stimulation program; an identification of one or more leads that are currently stimulating in the simulated stimulation program; an identification of one or more electrodes that are configured to be enabled in the simulated stimulation program; an identification of one or more leads that are configured to be enabled in the simulated stimulation program; and/or impedance information indicating a measured impedance. In some embodiments, the simulated neurostimulator information may include treatment data about a simulated treatment history of a simulated patient.

In some embodiments, the trainer device 900 may be configured to simulate a plurality of neurostimulators (for example, neurostimulators of different models and/or manufacturers). In some embodiments, a user of the trainer device 900 may be able to select a particular one of the plurality of neurostimulators to train for that particular neurostimulator. In some embodiments, the selection may be made prior to initiation of a connection between the trainer device 900 and the NP. For example, when the trainer device 900 is in range and turned on, the trainer device 900 may transmit to the NP information identifying a plurality of potential neurostimulators that may be simulated. The user may be presented (for example, on a display of the NP) with a prompt that lists the plurality of potential neurostimulators that may be simulated by the trainer device 900. In this example, the user may submit a selection input at the NP, selecting a particular one of the plurality of potential neurostimulators for training. The NP may then initiate a protocol for connecting to the trainer device 900. The protocol may include a transmission of information corresponding to the user selection to the trainer device 900. In response, the trainer device 900 may negotiate and establish a connection with the NP. From that point on and until instructed otherwise, the trainer device 900 may simulate the particular one of the plurality of potential neurostimulators. In some embodiments, the selection may be made after the connection between the trainer device and the NP is established. For example, the trainer device 900 may transmit to the NP information identifying a plurality of potential neurostimulators that may be simulated after the connection is established. The user may be presented with an initialization prompt that may list the plurality of potential neurostimulators that can be simulated. The initialization prompt may further request that the user select a particular one of the plurality of potential neurostimulators. In this example, the user may submit a selection input at the NP, selecting a particular one of the plurality of potential neurostimulators for training. The NP may transmit information corresponding to the user selection to the trainer device 900. In response, the trainer device 900 may, from that point on and until instructed otherwise, simulate the particular one of the plurality of potential neurostimulators. In particular embodiments, the plurality of potential neurostimulators may be updated at any time via a software update or patch of the trainer device 900. This may be advantageous, for example, because the trainer device 900 may be kept up-to-date and relevant as new models of neurostimulators are developed. In particular embodiments, the plurality of potential neurostimulators may include a plurality of IPGs and/or a plurality of EPGs. In particular embodiments, an interface surface the trainer device 900 may include one or more physical switches or buttons for selecting particular neurostimulators to simulate. For example, an interface surface of the trainer device 900 may include a first button that is dedicated to a first neurostimulator model and the second button that is dedicated to a second neurostimulator model. As another example interface surface of the trainer device 900 may include one or more cycling buttons for cycling through a sequence of different neurostimulator models that may be selected.

In some embodiments, the trainer device 900 may transmit a simulated first error information to the NP. The first error information may include an indication of a first error selected from a plurality of errors. In some embodiments, the plurality of errors may be stored within a data store of the trainer device 900. In some embodiments, the trainer device 900 may access this data store, select the first error, and transmit information about the first error to the NP. In some embodiments, the plurality of errors may be maintained (for example, within the data store of the trainer device 900) in a predetermined order. In these embodiments, the first error may be selected based on the predetermined order. Alternatively, the first error may be selected randomly or pseudo-randomly from the plurality of errors.

In some embodiments, the plurality of errors may include, for example: a low-battery condition indicating that a battery of the pulse generator is approaching a critically low level; a low-battery condition indicating that a battery of the NP is approaching a critically low level; a disconnected- or faulty-lead condition indicating that a lead may be disconnected or otherwise faulty; an excessive-temperature condition indicating that the simulated neurostimulator is above a respective threshold temperature; and/or an excessive-temperature condition indicating that the NP is above a respective threshold temperature.

In some embodiments, the trainer device 900 may transmit an instruction to the NP to display a simulation of an error (for example, the first error). In some embodiments, in response to receiving this instruction, the NP may cause an associated display to, for example, display an indication associated with the error. For example, it may display a message or warning corresponding to the error. Such a message or warning may be identical to or similar to a message or warning that may be displayed in response to a real (that is, non-simulated) error. In some embodiments, the trainer device 900 may also turn on an error indicator (for example, the error element 912) to indicate that an error is being simulated.

In some embodiments, the trainer device 900 may receive a response-information from the NP corresponding to one or more user inputs entered by a user to resolve the first error. In some embodiments, the NP may be configured to receive one or more response-inputs (for example, a user input) from a user in response to the simulation of a particular error. In some embodiments, the response-inputs may associated with a course of action intended to address the particular error. For example, in response to an error indicating an excessive-temperature condition of the IPG, the user may enter a response-input corresponding to reducing a simulated stimulation output or to turning off the IPG. In other embodiments, the response-inputs may simply indicate a confirmation from the user that the error has been acknowledged. For example, a user may enter a confirmation input in response to having received an error indicating a low-battery condition for a simulated IPG. In some embodiments, the response-inputs may be entered at the trainer device 900, for example, at one or more switch elements of the trainer device 900.

In some embodiments, the trainer device 900 may evaluate the response-inputs. That is, the trainer device 900 may evaluate whether the response-inputs from the user adequately address the error being simulated. In doing so, the trainer device 900 may access a memory (for example, a local memory) that may include information about response-inputs that may be appropriate to address each error. In these embodiments, if the trainer device 900 determines that a response-input adequately addresses the error being simulated, the trainer device 900 may register within a local memory of the trainer device 900 that the error has been resolved. If an error element 912 had been turned on due to the error, the trainer device 900 may turn off the error element 912.

In some embodiments, the evaluation of the response-inputs may occur on the NP. That is, the NP may evaluate whether the response-inputs from the user adequately address the error being simulated. In doing so, the NP may access a memory (for example, a local memory) that may include information about response-inputs that may be appropriate to address each error. In these embodiments, if the NP determines that a response-input adequately addresses the error being simulated, the NP may transmit error-resolution information to the trainer device 900, indicating that the first error has been resolved. In response to receiving the error-resolution information, the trainer device 900 may register within a local memory of the trainer device 900 that the error has been resolved. If an error element 912 had been turned on due to the error, the trainer device 900 may turn off the error element 912. In some embodiments, the evaluation may occur partly on the trainer device 900 and partly on the NP.

In some embodiments, the trainer device 900 may transmit a simulated second error information to the NP. The second error information may include an indication of a second error selected from the plurality of errors. In some embodiments, in cases where the plurality of errors is maintained in a predetermined order, the second error may be next in sequence from the first error based on the predetermined order. In some embodiments, the second error may be selected only when it is determined that the first error has been resolved. In other embodiments, the second error may be transmitted only when it is determined that the first error has been resolved, but may be selected before the first error has been resolved.

In some embodiments, the trainer device 900 may receive a mode-selection input for cycling between or among two or more pulse-generator modes. The pulse-generator modes may include an IPG mode and an EPG mode. In response, the trainer device 900 may select a respective pulse-generator mode associated with the received mode selection input. For example, referencing FIG. 9, in the case where the trainer device 900 is currently in an IPG mode, the trainer device 900 may switch from the IPG mode to an EPG mode in response to a user input resulting from a user pressing the switch 920.

In some embodiments, the trainer device 900 may be used to simulate a variety of programming situations other than errors. For example, the trainer device 900 may be used to simulate more ordinary tasks such as the programming of patient stimulation patterns, the programming of modes, the task of switching between modes. the adjusting of parameters, or any other suitable task. Essentially, the trainer device 900 may be used to simulate any tasks that an IPG or EPG may perform.

FIG. 11 illustrates a schematic diagram of an example trainer device 900 having separated first and second circuitry. In some embodiments, referencing FIG. 11, the stimulation of the programming of the neurostimulator may be performed using, at least in part, a first circuitry 1110 of the trainer device 900. In some embodiments, the first circuitry 1110 may include a PCB that may be configured to be coupled (for example, wirelessly or via a wired connection) communicatively to the NP, so that the trainer device 900 and the NP may communicate with each other to generate and display the training simulations described herein.

FIG. 12 illustrates an example method 1200 for simulating an error during a simulated neurostimulator programming session. The method may begin at step 1210, where a trainer device may be coupled to a NP, wherein the NP is configured to program or adjust parameters of one or more neurostimulators, and wherein the trainer device is configured to simulate the one or more neurostimulators. At step 1220, the trainer device may transmit simulated neurostimulator information to the NP, wherein the simulated neurostimulator information comprises one or more stimulation parameters or information associated with one or more leads. At step 1230, the trainer device may transmit a simulated first error information to the NP, wherein the first error information comprises an indication of a first error selected from a plurality of errors. At step 1240, the trainer device may receive a response-information from the NP corresponding to a user input entered by a user to resolve the first error. At step 1250, the trainer device may register within a local memory of the trainer device that the first error has been resolved. Particular embodiments may repeat one or more steps of the method of FIG. 12, where appropriate. Although this disclosure describes and illustrates particular steps of the method of FIG. 12 as occurring in a particular order, this disclosure contemplates any suitable steps of the method of FIG. 12 occurring in any suitable order. Moreover, although this disclosure describes and illustrates an example method for simulating an error during a simulated neurostimulator programming session including the particular steps of the method of FIG. 12, this disclosure contemplates any suitable method for simulating an error during a simulated neurostimulator programming session, including any suitable steps, which may include all, some, or none of the steps of the method of FIG. 12, where appropriate. Furthermore, although this disclosure describes and illustrates particular components, devices, or systems carrying out particular steps of the method of FIG. 12, this disclosure contemplates any suitable combination of any suitable components, devices, or systems carrying out any suitable steps of the method of FIG. 12.

FIG. 13 illustrates an example method 1300 for simulating neurostimulation lead placement. The method may begin at step 1310, where a lead stimulation cable of a neurostimulator training system may be connected to a first port of a NP. At step 1320, a ground of the neurostimulator training system may be connected to a second port of the NP. At step 1330, the lead-placement circuitry of the neurostimulator training system may receive one or more electrical pulses from the NP, wherein the one or more electrical pulses form a completed circuit comprising the lead stimulation cable, the ground electrode cable, and the fixed load. At step 1340, the neurostimulator training system may measure an impedance of the completed circuit, wherein the impedance is associated with at least the fixed load. At step 1350, the neurostimulator training system Particular embodiments may repeat one or more steps of the method of FIG. 13, where appropriate. Although this disclosure describes and illustrates particular steps of the method of FIG. 13 as occurring in a particular order, this disclosure contemplates any suitable steps of the method of FIG. 13 occurring in any suitable order. Moreover, although this disclosure describes and illustrates an example method for simulating neurostimulation lead placement including the particular steps of the method of FIG. 13, this disclosure contemplates any suitable method for simulating neurostimulation lead placement, including any suitable steps, which may include all, some, or none of the steps of the method of FIG. 13, where appropriate. Furthermore, although this disclosure describes and illustrates particular components, devices, or systems carrying out particular steps of the method of FIG. 13, this disclosure contemplates any suitable combination of any suitable components, devices, or systems carrying out any suitable steps of the method of FIG. 13.

In some embodiments, the trainer device 900 may be used to provide a lead placement simulation, which may be a simulation of the checks involved in ensuring proper placement of a lead. One of these checks may include measuring and impedance, which may confirm that a lead has been implanted within tissue, or within a particular type of tissue associated with a signature impedance. For example, a clinician implanting a lead may check to confirm that the lead has been implanted in an area that provides an appropriate impedance value (for example, an impedance value that is within a threshold range of a specified impedance value associated with a target tissue). Alternatively or additionally, an impedance measurement may be used to indicate that a reliable connection has been made between a lead and an IPG or an EPG and/or that the lead is intact. This may be used as an initial step in positioning the lead and/or in programming the leads to ensure the electrodes are properly functioning. In some embodiments, the specified impedance value may be around 500 ohms.

In some embodiments, the lead placement simulation may be provided when the trainer device 900 is operating in a different mode, termed herein as “Lead Placement Mode.” In some embodiments, for example referencing FIG. 11, the trainer device 900 may include a second circuitry 1120. In some embodiments, the trainer device 900 may include one or more cables for lead placement simulation. These cables may be configured for connection to the NP. For example, the cables may include a foramen needle stimulation cable 930, a ground electrode cable 932, and a lead stimulation cable 940 for simulating a lead (for example, a cable for simulating a four-channel lead or a five-channel lead). In some embodiments, the NP may include circuitry that is configured to output a pulse with predetermined characteristics (for example, a predetermined voltage) via the cables to a circuit portion 920 within the trainer device 900. The trainer device 900 may include a load 1125 (which may include one or more resistors) within the portable housing 902 that may provide a “dummy” impedance, through which the pulse may travel. In some embodiments, the load 1125 may be part of the second circuitry 1120. The trainer device 900 (or alternatively, the NP to which the trainer device 900 is connected) may be able to confirm the impedance provided by the load. In some embodiments, the second circuitry may be separated from the first circuitry 1110 that is used to simulate the EPG or IPG. For example, the second circuitry 1120 may be disposed at least in part on a separate PCB, and may be isolated from a PCB of the second circuitry 1120. Disposing the second circuitry 1120 on a separate PCB may be advantageous in that such separation of the different circuitries may permit easier modification of the second circuitry 1120 without the risk of affecting the first circuitry 1110. For example, this may allow for easy modification of the load 1125 in the second circuitry 1120 to change the simulated lead impedance values (for example, replacing a 500-ohm resistor that may be in the load 1125 with a 600-ohm resistor). Alternatively, such separation may permit easier modification of the first circuitry 1110 without the risk of affecting the second circuitry 1120.

In some embodiments, the lead placement simulation may include, for example, two phases: (1) the foramen needle insertion phase and (2) the lead insertion phase. The foramen needle insertion phase may simulate the task of inserting a foramen needle into a tissue near a target nerve. In a real medical procedure, the insertion of the foramen needle may be done, for example, to identify the optimal stimulation location, as described elsewhere herein. In some embodiments, referencing FIG. 10, the simulation for the foramen needle insertion phase may involve the user of the trainer device 900 connecting the foramen needle stimulation cable 930 and the ground electrode cable 932 to suitable ports of the NP 1010. For example, the foramen needle stimulation cable 930 may be connected to a first port of the NP 1010 and the ground electrode cable 932 may be connected to a second port of the NP 1010. In some embodiments, following activation of Lead Placement Mode, the NP may output a pulse, completing a circuit that may include the foramen needle stimulation cable 930 and the ground electrode cable 932. The circuit may include the load 1125, which may provide an impedance that simulates a target tissue. In some embodiments, the circuit may also include one or more other fixed loads (for example, a 100-ohm resistor, disposed within the NP, in series with the load 1125 when the circuit is completed). In some embodiments, the trainer device 900 may be able to measure the impedance of the circuit, which includes the impedance provided by the load 1125. For example, the trainer device may receive, at the second circuitry 1120, one or more electrical pulses from the NP, wherein the one or more electrical pulses form a completed circuit that includes at least the foramen needle stimulation cable, the ground electrode cable, and the fixed load of the second circuitry. The trainer device 900 may measure an impedance of the completed circuit, wherein the impedance is associated with at least the fixed load. The trainer device 900 may then transmit, to the NP, information corresponding to the measured impedance. In other embodiments, the NP may make this measurement (that is, the measurement step may occur on the NP).

The impedance measurement may be based on, for example, measuring the voltage differential or the current in the circuit (for example, using Ohm's law, V=IR). As an example, the impedance of the load 1125 may be around 499 ohms. The measured impedance may be around 499 ohms, or alternatively may be higher based on the presence of one or more other fixed loads. For example, the circuit may have a 100-ohm resistor in series with the foramen needle connection and a 100-ohm resistor in series with the ground electrode connection, which may result in a measured impedance of 699 ohms. The measured impedance may be displayed on a display, for example a display associated with the NP 1010 or a display associated with the trainer device 900. The user of the trainer device 900 may be able to view the measured impedance on the display and determine that the simulated foramen needle has been placed in a simulated location that provides the correct impedance.

In the lead insertion phase of the lead placement simulation, the trainer device 900 may simulate the implantation of one or more leads of an IPG or EPG. As an example, FIGS. 9-10 illustrate a configuration that may be used to training for a single lead, the implantation of which may be simulated by the lead stimulation cable 940. The user may connect the ground electrode cable 932 and the lead stimulation cable 940 to suitable ports of the NP 1010. As with the foramen needle insertion phase, the clinician programmer may output a pulse with predetermined characteristics, completing a circuit that includes the ground electrode cable 932 lead stimulation cable 940. The circuit may also include the load 1125. Similar to the foramen needle insertion phase, in some embodiments, the trainer device 900 may be able to measure the impedance of the circuit, which includes the impedance provided by the load 1125. For example, the trainer device may receive, at the second circuitry 1120, one or more electrical pulses from the NP, wherein the one or more electrical pulses form a completed circuit that includes at least the lead stimulation cable, the ground electrode cable, and the fixed load of the second circuitry. The trainer device 900 may measure an impedance of the completed circuit, wherein the impedance is associated with at least the fixed load. The trainer device 900 may then transmit, to the NP, information corresponding to the measured impedance. In other embodiments, again similar to the foramen needle insertion phase, the NP may make this measurement (that is, the measurement step may occur on the NP).

In some embodiments, the circuit for the lead insertion phase may include one or more other fixed loads. For example, the circuit may include a 100-ohm resistor in series with the ground electrode connection. In this example, a load 1125 that has an impedance of 499 ohms may yield measured impedance of 599 ohms. The measured impedance may be displayed, for example, on a display associated with the NP. The user of the trainer device 900 may be able to view the measured impedance on the display and determine that the simulated lead has been placed in a simulated location that provides the correct impedance.

In some embodiments, Lead Placement Mode may be initiated when the user manually activates the mode. For example, the user may activate this mode by actuating an appropriate button on the clinician programmer or the trainer device 900. In some embodiments, this mode may be automatically activated by the trainer device 900 when the user simply plugs in the cables associated with the lead placement mode.

In the foregoing specification, the invention is described with reference to specific embodiments thereof, but those skilled in the art will recognize that the invention is not limited thereto. Various features and aspects of the above-described invention can be used individually or jointly. Further, the invention can be utilized in any number of environments and applications beyond those described herein without departing from the broader spirit and scope of the specification. The specification and drawings are, accordingly, to be regarded as illustrative rather than restrictive. It will be recognized that the terms “comprising,” “including,” and “having,” as used herein, are specifically intended to be read as open-ended terms of art.

Claims

1. A method of providing a simulation of a neurostimulator programming session, the method comprising: coupling a trainer device to a neurostimulator programmer (NP), wherein the NP is configured to program or adjust parameters of one or more neurostimulators, and wherein the trainer device is configured to simulate the one or more neurostimulators;by the circuitry of the trainer device, transmitting a simulated first error information to the NP, wherein the first error information comprises an indication of a first error selected from a plurality of errors; andby the circuitry of the trainer device, receiving a response-information from the NP corresponding to a user input entered by a user to resolve the first error.
2. The method of claim 1, wherein the NP is a clinician programmer, and wherein the one or more neurostimulators that the trainer device is configured to simulate comprises an implantable pulse generator (IPG) or an external pulse generator (EPG).
3. The method of claim 1, further comprising transmitting simulated neurostimulator information to the NP, wherein the simulated neurostimulator information comprises battery information of a simulated one of the one or more neurostimulators.
4. The method of claim 1, further comprising transmitting simulated neurostimulator information to the NP, wherein the simulated neurostimulator information comprises simulated current information related to a simulated stimulation program, the current information comprising: one or more stimulation parameters;an indication of whether stimulation is currently ON or OFF in the simulated stimulation program;an identification of one or more electrodes that are currently stimulating in the simulated stimulation program;an identification of one or more leads that are currently stimulating in the simulated stimulation program;an identification of one or more electrodes that are configured to be enabled in the simulated stimulation program;an identification of one or more leads that are configured to be enabled in the simulated stimulation program; orimpedance information indicating a measured impedance.
5. The method of claim 1, further comprising transmitting simulated neurostimulator information to the NP, wherein the simulated neurostimulator information further comprises treatment data about a simulated treatment history of a simulated patient.
6. The method of claim 1, further comprising: accessing a data store of the trainer device, wherein the data store comprises a plurality of errors; andselecting the first error from the plurality of errors.
7. The method of claim 6, wherein the plurality of errors is maintained in a predetermined order, and wherein the first error is selected based on the predetermined order.
8. The method of claim 6, wherein the first error is selected at random from the plurality of errors.
9. The method of claim 6, wherein the plurality of errors comprises a low-battery condition indicating that a battery of a simulated one of the one or more neurostimulators is approaching a critically low level.
10. The method of claim 6, wherein the plurality of errors comprises a disconnected- or faulty-lead condition indicating that a lead is disconnected or otherwise faulty.
11. The method of claim 6, wherein the plurality of errors comprises an excessive-temperature condition indicating that a simulated one of the one or more neurostimulators is above a respective threshold temperature, or an excessive-temperature condition indicating that the NP is above a respective threshold temperature.
12. The method of claim 1, further comprising: transmitting a simulated second error information to the NP, wherein: the second error information comprises an indication of a second error selectedfrom the plurality of errors, the plurality of errors is maintained in a predetermined order, andthe second error is next in sequence based on the predetermined order from the first error.
13. The method of claim 1, further comprising: receiving a mode-selection input for cycling between or among two or more pulse-generator modes, wherein the pulse-generator modes comprise an IPG mode and an EPG mode; andselecting a respective pulse-generator mode associated with the received mode-selection input.
14. The method of claim 1, further comprising: receiving a user input requesting an error simulation; andin response to receiving the user input, transmitting an instruction to the NP to display a simulation of the first error.
15. The method of claim 14, further comprising: turning on an error indicator associated with the trainer device that indicates that an error is being simulated;evaluating the response-information to determine if the corresponding user input resolves the first error; andin response to determining that the corresponding user input resolves the first error, turning off the error indicator.
16. The method of claim 14, further comprising: turning on an error indicator associated with the trainer device that indicates that an error is being simulated;receiving error-resolution information from the NP indicating that the first error has been resolved; andin response to receiving the error-resolution information, turning off the error indicator.
17. The method of claim 1, further comprising: turning on one or more indicators on an interface of the trainer device, wherein the one or more indicators comprise:a stimulation indicator that indicates whether or not the NP has successfully sent a command to the trainer device to turn on patient stimulation;one or more pulse-generator mode indicators that indicate whether the simulation is simulating an IPG or an EPG; orone or more error indicators that indicate whether an error is being simulated.
18. The method of claim 1, wherein the circuitry comprises: a first circuitry for simulating the one or more neurostimulators; anda second circuitry for simulating placement of a lead, wherein the second circuitry comprises a fixed load.
19. The method of claim 18, wherein the trainer device comprises a foramen needle stimulation cable and a ground electrode cable, wherein the foramen needle stimulation cable is configured to be connected to a first port of the NP, and wherein the ground electrode cable is configured to be connected to a second port of the NP, the method further comprising: receiving, at the second circuitry, one or more electrical pulses from the NP, wherein the one or more electrical pulses form a completed circuit comprising the foramen needle stimulation cable, the ground electrode cable, and the fixed load of the second circuitry;measuring an impedance of the completed circuit, wherein the impedance is associated with at least the fixed load; andtransmitting, to the NP, information corresponding to the measured impedance.
20. The method of claim 19, wherein the first circuitry and the second circuitry are housed on separate circuit boards that are not electrically coupled to each other.
21. The method of claim 18, wherein the trainer device comprises a lead stimulation cable and a ground electrode cable, wherein the lead stimulation cable is configured to be connected to a first port of the NP, and wherein the ground electrode cable is configured to be connected to a second port of the NP, the method further comprising: receiving, at the second circuitry, one or more electrical pulses from the NP, wherein the one or more electrical pulses form a completed circuit comprising the lead stimulation cable, the ground electrode cable, and the fixed load of the second circuitry;measuring an impedance of the completed circuit, wherein the impedance is associated with at least the fixed load; andtransmitting, to the NP, information corresponding to the measured impedance.
22. The method of claim 21, wherein the first circuitry and the second circuitry are housed on separate circuit boards that are not electrically coupled to each other.
23. The method of claim 1, wherein one or more retention pins of the trainer device is configured to be secured to one or more open ports of the NP.
24. The method of claim 1, wherein the trainer device is coupled to the NP wirelessly.
25. The method of claim 1, further comprising registering within a local memory of the trainer device that the first error has been resolved.
26. A trainer device for providing a simulation of a neurostimulator programming session, the trainer device comprising: a portable housing;circuitry disposed within the portable housing, wherein the circuitry is configured to: couple the trainer device to a neurostimulator programmer (NP), wherein the NP is configured to program or adjust parameters of one or more neurostimulators, and wherein the trainer device is configured to simulate the one or more neurostimulators;transmit a simulated first error information to the NP, wherein the first error information comprises an indication of a first error selected from a plurality of errors; andreceive a response-information from the NP corresponding to a user input entered by a user to resolve the first error.
27. A neurostimulator training system comprising: a neurostimulator programmer (NP) configured to program or adjust parameters of one or more neurostimulators; anda trainer device comprising: a portable housing;circuitry disposed within the portable housing, wherein the circuitry is configured to: couple the trainer device to a NP, wherein the trainer device is configured to simulate the one or more neurostimulators;transmit a simulated first error information to the NP, wherein the first error information comprises an indication of a first error selected from a plurality of errors; andreceive a response-information from the NP corresponding to a user input entered by a user to resolve the first error.

CROSS-REFERENCES TO RELATED APPLICATIONS

The present application claims the benefit of priority of U.S. Provisional Application No. 62/852,875 filed on May 24, 2019; and entitled “TRAINER FOR A NEUROSTIMULATOR PROGRAMMER AND ASSOCIATED METHODS OF USE WITH A NEUROSTIMULATION SYSTEM,” the entirety of which is hereby incorporated by reference herein.

US Referenced Citations (949)

Number	Name	Date	Kind
53928	Sheffield et al.	Apr 1866	A
3057356	Greatbatch	Oct 1962	A
3348548	Chardack	Oct 1967	A
3646940	Timm et al.	Mar 1972	A
3824129	Fagan, Jr.	Jul 1974	A
3825015	Berkovits	Jul 1974	A
3888260	Fischell	Jun 1975	A
3902501	Citron et al.	Sep 1975	A
3939843	Smyth	Feb 1976	A
3942535	Schulman	Mar 1976	A
3970912	Hoffman	Jul 1976	A
3995623	Blake et al.	Dec 1976	A
4019518	Maurer et al.	Apr 1977	A
4044774	Corbin et al.	Aug 1977	A
4082097	Mann et al.	Apr 1978	A
4141365	Fischell et al.	Feb 1979	A
4166469	Littleford	Sep 1979	A
4210383	Davis	Jul 1980	A
4269198	Stokes	May 1981	A
4285347	Hess	Aug 1981	A
4340062	Thompson et al.	Jul 1982	A
4379462	Borkan et al.	Apr 1983	A
4407303	Akerstrom	Oct 1983	A
4437475	White	Mar 1984	A
4468723	Hughes	Aug 1984	A
4512351	Pohndorf	Apr 1985	A
4550731	Batina et al.	Nov 1985	A
4558702	Barreras et al.	Dec 1985	A
4654880	Sontag	Mar 1987	A
4662382	Sluetz et al.	May 1987	A
4673867	Davis	Jun 1987	A
4719919	Marchosky et al.	Jan 1988	A
4721118	Harris	Jan 1988	A
4722353	Sluetz	Feb 1988	A
4744371	Harris	May 1988	A
4800898	Hess et al.	Jan 1989	A
4848352	Pohndorf et al.	Jul 1989	A
4860446	Lessar et al.	Aug 1989	A
4957118	Erlebacher	Sep 1990	A
4989617	Memberg et al.	Feb 1991	A
5012176	Laforge	Apr 1991	A
5052407	Hauser et al.	Oct 1991	A
5143089	Alt	Sep 1992	A
5193539	Schulman et al.	Mar 1993	A
5197466	Marchosky et al.	Mar 1993	A
5204611	Nor et al.	Apr 1993	A
5255691	Otten	Oct 1993	A
5257634	Kroll	Nov 1993	A
5342408	deCoriolis et al.	Aug 1994	A
5439485	Mar et al.	Aug 1995	A
5476499	Hirschberg	Dec 1995	A
5484445	Knuth	Jan 1996	A
5571148	Loeb et al.	Nov 1996	A
5592070	Mino	Jan 1997	A
5637981	Nagai et al.	Jun 1997	A
5676162	Larson, Jr. et al.	Oct 1997	A
5690693	Wang et al.	Nov 1997	A
5702428	Tippey et al.	Dec 1997	A
5702431	Wang et al.	Dec 1997	A
5712795	Layman et al.	Jan 1998	A
5713939	Nedungadi et al.	Feb 1998	A
5733313	Barreras, Sr. et al.	Mar 1998	A
5735887	Barreras, Sr. et al.	Apr 1998	A
5741316	Chen et al.	Apr 1998	A
5871532	Schroeppel	Feb 1999	A
5876423	Braun	Mar 1999	A
5877472	Campbell et al.	Mar 1999	A
5902331	Bonner et al.	May 1999	A
5948006	Mann	Sep 1999	A
5949632	Barreras, Sr. et al.	Sep 1999	A
5957965	Moumane et al.	Sep 1999	A
5974344	Shoemaker, II et al.	Oct 1999	A
5991665	Wang et al.	Nov 1999	A
6014588	Fitz	Jan 2000	A
6027456	Feler et al.	Feb 2000	A
6035237	Schulman et al.	Mar 2000	A
6052624	Mann	Apr 2000	A
6055456	Gerber	Apr 2000	A
6057513	Ushikoshi et al.	May 2000	A
6067474	Schulman et al.	May 2000	A
6075339	Reipur et al.	Jun 2000	A
6076017	Taylor et al.	Jun 2000	A
6081097	Seri et al.	Jun 2000	A
6083247	Rutten et al.	Jul 2000	A
6104957	Alo et al.	Aug 2000	A
6104960	Duysens et al.	Aug 2000	A
6138681	Chen et al.	Oct 2000	A
6157861	Faltys et al.	Dec 2000	A
6164284	Schulman et al.	Dec 2000	A
6165180	Cigaina et al.	Dec 2000	A
6166518	Echarri et al.	Dec 2000	A
6169387	Kaib	Jan 2001	B1
6172556	Prentice	Jan 2001	B1
6178353	Griffith et al.	Jan 2001	B1
6181105	Cutolo et al.	Jan 2001	B1
6181961	Prass	Jan 2001	B1
6185452	Schulman et al.	Feb 2001	B1
6191365	Avellanet	Feb 2001	B1
6208894	Schulman et al.	Mar 2001	B1
6208895	Sullivan et al.	Mar 2001	B1
6212430	Kung	Apr 2001	B1
6212431	Hahn et al.	Apr 2001	B1
6221513	Lasater	Apr 2001	B1
6227204	Baumann et al.	May 2001	B1
6243608	Pauly et al.	Jun 2001	B1
6246911	Seligman	Jun 2001	B1
6249703	Stanton et al.	Jun 2001	B1
6265789	Honda et al.	Jul 2001	B1
6275737	Mann	Aug 2001	B1
6278258	Echarri et al.	Aug 2001	B1
6305381	Weijand et al.	Oct 2001	B1
6306100	Prass	Oct 2001	B1
6313779	Leung et al.	Nov 2001	B1
6314325	Fitz	Nov 2001	B1
6315721	Schulman et al.	Nov 2001	B2
6316909	Honda et al.	Nov 2001	B1
6321118	Hahn	Nov 2001	B1
6324432	Rigaux et al.	Nov 2001	B1
6327504	Dolgin et al.	Dec 2001	B1
6354991	Gross et al.	Mar 2002	B1
6360750	Gerber et al.	Mar 2002	B1
6381496	Meadows et al.	Apr 2002	B1
6393325	Mann et al.	May 2002	B1
6427086	Fischell et al.	Jul 2002	B1
6438423	Rezai et al.	Aug 2002	B1
6442434	Zarinetchi et al.	Aug 2002	B1
6453198	Torgerson et al.	Sep 2002	B1
6466817	Kaula et al.	Oct 2002	B1
6473652	Sarwal et al.	Oct 2002	B1
6500141	Irion et al.	Dec 2002	B1
6505075	Weiner	Jan 2003	B1
6505077	Kast et al.	Jan 2003	B1
6510347	Borkan	Jan 2003	B2
6516227	Meadows et al.	Feb 2003	B1
6517227	Stidham et al.	Feb 2003	B2
6521350	Fey et al.	Feb 2003	B2
6542846	Miller et al.	Apr 2003	B1
6553263	Meadows et al.	Apr 2003	B1
6564807	Schulman et al.	May 2003	B1
6584355	Stessman	Jun 2003	B2
6587728	Fang et al.	Jul 2003	B2
6600954	Cohen et al.	Jul 2003	B2
6609031	Law et al.	Aug 2003	B1
6609032	Woods et al.	Aug 2003	B1
6609945	Jimenez et al.	Aug 2003	B2
6625494	Fang et al.	Sep 2003	B2
6652449	Gross et al.	Nov 2003	B1
6654634	Prass	Nov 2003	B1
6662051	Eraker et al.	Dec 2003	B1
6662053	Borkan	Dec 2003	B2
6664763	Echarri et al.	Dec 2003	B2
6678563	Fang et al.	Jan 2004	B2
6685638	Taylor et al.	Feb 2004	B1
6701189	Fang et al.	Mar 2004	B2
6721603	Zabara et al.	Apr 2004	B2
6735474	Loeb et al.	May 2004	B1
6745077	Griffith et al.	Jun 2004	B1
6809701	Amundson et al.	Oct 2004	B2
6836684	Rijkhoff et al.	Dec 2004	B1
6836685	Fitz	Dec 2004	B1
6847849	Mamo et al.	Jan 2005	B2
6864755	Moore	Mar 2005	B2
6871099	Whitehurst et al.	Mar 2005	B1
6892098	Ayal et al.	May 2005	B2
6895280	Meadows et al.	May 2005	B2
6896651	Gross et al.	May 2005	B2
6901287	Davis et al.	May 2005	B2
6907293	Grill et al.	Jun 2005	B2
6923814	Hildebrand et al.	Aug 2005	B1
6941171	Mann et al.	Sep 2005	B2
6959215	Gliner et al.	Oct 2005	B2
6971393	Mamo et al.	Dec 2005	B1
6986453	Jiang et al.	Jan 2006	B2
6989200	Byers et al.	Jan 2006	B2
6990376	Tanagho et al.	Jan 2006	B2
6999819	Swoyer et al.	Feb 2006	B2
7010351	Firlik et al.	Mar 2006	B2
7024247	Gliner et al.	Apr 2006	B2
7043304	Griffith et al.	May 2006	B1
7047078	Boggs, II et al.	May 2006	B2
7051419	Schrom et al.	May 2006	B2
7054689	Whitehurst et al.	May 2006	B1
7069081	Biggs et al.	Jun 2006	B2
7114502	Schulman et al.	Oct 2006	B2
7127298	He et al.	Oct 2006	B1
7131996	Wasserman et al.	Nov 2006	B2
7142925	Bhadra et al.	Nov 2006	B1
7146217	Firlik et al.	Dec 2006	B2
7146219	Sieracki et al.	Dec 2006	B2
7151914	Brewer	Dec 2006	B2
7167743	Heruth et al.	Jan 2007	B2
7167749	Biggs et al.	Jan 2007	B2
7167756	Torgerson et al.	Jan 2007	B1
7177677	Kaula et al.	Feb 2007	B2
7177690	Woods et al.	Feb 2007	B2
7177698	Klosterman et al.	Feb 2007	B2
7181286	Sieracki et al.	Feb 2007	B2
7184836	Meadows et al.	Feb 2007	B1
7187978	Malek et al.	Mar 2007	B2
7191005	Stessman	Mar 2007	B2
7212110	Martin et al.	May 2007	B1
7214197	Prass	May 2007	B2
7216001	Hacker et al.	May 2007	B2
7225028	Della Santina et al.	May 2007	B2
7225032	Schmeling et al.	May 2007	B2
7231254	DiLorenzo	Jun 2007	B2
7234853	Givoletti	Jun 2007	B2
7236831	Firlik et al.	Jun 2007	B2
7239918	Strother et al.	Jul 2007	B2
7245972	Davis	Jul 2007	B2
7283867	Strother et al.	Oct 2007	B2
7286880	Olson et al.	Oct 2007	B2
7295878	Meadows et al.	Nov 2007	B1
7299096	Balzer et al.	Nov 2007	B2
7305268	Gliner et al.	Dec 2007	B2
7317948	King et al.	Jan 2008	B1
7324852	Barolat et al.	Jan 2008	B2
7324853	Ayal et al.	Jan 2008	B2
7326181	Katims	Feb 2008	B2
7328068	Spinelli et al.	Feb 2008	B2
7330764	Swoyer et al.	Feb 2008	B2
7331499	Jiang et al.	Feb 2008	B2
7337006	Kim et al.	Feb 2008	B2
7359751	Erickson et al.	Apr 2008	B1
7369894	Gerber	May 2008	B2
7386348	North et al.	Jun 2008	B2
7387603	Gross et al.	Jun 2008	B2
7395113	Heruth et al.	Jul 2008	B2
7396265	Darley et al.	Jul 2008	B2
7406351	Wesselink	Jul 2008	B2
7415308	Gerber et al.	Aug 2008	B2
7444181	Shi et al.	Oct 2008	B2
7444184	Boveja et al.	Oct 2008	B2
7447546	Kim et al.	Nov 2008	B2
7450991	Smith et al.	Nov 2008	B2
7450993	Kim et al.	Nov 2008	B2
7460911	Cosendai et al.	Dec 2008	B2
7463928	Lee et al.	Dec 2008	B2
7470236	Kelleher et al.	Dec 2008	B1
7483747	Gliner et al.	Jan 2009	B2
7483752	Von Arx et al.	Jan 2009	B2
7486048	Tsukamoto et al.	Feb 2009	B2
7496404	Meadows et al.	Feb 2009	B2
7502651	Kim et al.	Mar 2009	B2
7513257	Schulman et al.	Apr 2009	B2
7515965	Gerber et al.	Apr 2009	B2
7515967	Phillips et al.	Apr 2009	B2
7522953	Kaula et al.	Apr 2009	B2
7532936	Erickson et al.	May 2009	B2
7539538	Parramon et al.	May 2009	B2
7551958	Libbus et al.	Jun 2009	B2
7551960	Forsberg et al.	Jun 2009	B2
7555346	Woods et al.	Jun 2009	B1
7555347	Loeb	Jun 2009	B2
7565199	Sheffield et al.	Jul 2009	B2
7565203	Greenberg et al.	Jul 2009	B2
7571000	Boggs, II et al.	Aug 2009	B2
7577481	Firlik et al.	Aug 2009	B2
7578819	Bleich et al.	Aug 2009	B2
7580752	Gerber et al.	Aug 2009	B2
7580753	Kim et al.	Aug 2009	B2
7582053	Gross et al.	Sep 2009	B2
7582058	Miles et al.	Sep 2009	B1
7613516	Cohen et al.	Nov 2009	B2
7617002	Goetz	Nov 2009	B2
7620456	Gliner et al.	Nov 2009	B2
7623925	Grill et al.	Nov 2009	B2
7636602	Baru Fassio et al.	Dec 2009	B2
7640059	Forsberg et al.	Dec 2009	B2
7643880	Tanagho et al.	Jan 2010	B2
7647117	Bauhahn	Jan 2010	B2
7650192	Wahlstrand	Jan 2010	B2
7664544	Miles et al.	Feb 2010	B2
7672730	Firlik et al.	Mar 2010	B2
7706889	Gerber et al.	Apr 2010	B2
7720547	Denker et al.	May 2010	B2
7720548	King	May 2010	B2
7725191	Greenberg et al.	May 2010	B2
7734355	Cohen et al.	Jun 2010	B2
7738963	Hickman et al.	Jun 2010	B2
7738965	Phillips et al.	Jun 2010	B2
7747330	Nolan et al.	Jun 2010	B2
7756584	Sheffield et al.	Jul 2010	B2
7771838	He et al.	Aug 2010	B1
7774069	Olson et al.	Aug 2010	B2
7801601	Maschino et al.	Sep 2010	B2
7801619	Gerber et al.	Sep 2010	B2
7805196	Miesel et al.	Sep 2010	B2
7813803	Heruth et al.	Oct 2010	B2
7813809	Strother et al.	Oct 2010	B2
7819909	Goetz et al.	Oct 2010	B2
7826901	Lee et al.	Nov 2010	B2
7831305	Gliner	Nov 2010	B2
7848818	Barolat et al.	Dec 2010	B2
7853322	Bourget et al.	Dec 2010	B2
7878207	Goetz et al.	Feb 2011	B2
7890176	Jaax et al.	Feb 2011	B2
7904167	Klosterman et al.	Mar 2011	B2
7912555	Swoyer et al.	Mar 2011	B2
7925357	Phillips et al.	Apr 2011	B2
7932696	Peterson	Apr 2011	B2
7933656	Sieracki et al.	Apr 2011	B2
7935051	Miles et al.	May 2011	B2
7937158	Erickson et al.	May 2011	B2
7945330	Gliner et al.	May 2011	B2
7952349	Huang et al.	May 2011	B2
7957797	Bourget et al.	Jun 2011	B2
7957809	Bourget et al.	Jun 2011	B2
7957818	Swoyer	Jun 2011	B2
7962218	Balzer et al.	Jun 2011	B2
7966073	Pless et al.	Jun 2011	B2
7979119	Kothandaraman et al.	Jul 2011	B2
7979126	Payne et al.	Jul 2011	B2
7981144	Geist et al.	Jul 2011	B2
7988507	Darley et al.	Aug 2011	B2
8000782	Gharib et al.	Aug 2011	B2
8000800	Takeda et al.	Aug 2011	B2
8000805	Swoyer et al.	Aug 2011	B2
8005535	Gharib et al.	Aug 2011	B2
8005549	Boser et al.	Aug 2011	B2
8005550	Boser et al.	Aug 2011	B2
8019423	Possover	Sep 2011	B2
8019425	Firlik et al.	Sep 2011	B2
8024047	Olson et al.	Sep 2011	B2
8027716	Gharib et al.	Sep 2011	B2
8036756	Swoyer et al.	Oct 2011	B2
8044635	Peterson	Oct 2011	B2
8050753	Libbus et al.	Nov 2011	B2
8050767	Sheffield et al.	Nov 2011	B2
8050768	Firlik et al.	Nov 2011	B2
8050769	Gharib et al.	Nov 2011	B2
8055337	Moffitt et al.	Nov 2011	B2
8055349	Gharib et al.	Nov 2011	B2
8065012	Firlik et al.	Nov 2011	B2
8068912	Kaula et al.	Nov 2011	B2
8073546	Sheffield et al.	Dec 2011	B2
8082039	Kim et al.	Dec 2011	B2
8083663	Gross et al.	Dec 2011	B2
8103360	Foster	Jan 2012	B2
8108049	King	Jan 2012	B2
8112155	Einav et al.	Feb 2012	B2
8116862	Stevenson et al.	Feb 2012	B2
8121701	Woods et al.	Feb 2012	B2
8121702	King	Feb 2012	B2
8129942	Park et al.	Mar 2012	B2
8131358	Moffitt et al.	Mar 2012	B2
8140168	Olson et al.	Mar 2012	B2
8145324	Stevenson et al.	Mar 2012	B1
8147421	Farquhar et al.	Apr 2012	B2
8150530	Wesselink	Apr 2012	B2
8155753	Wesselink	Apr 2012	B2
8175717	Haller et al.	May 2012	B2
8180451	Hickman et al.	May 2012	B2
8180452	Shaquer	May 2012	B2
8180461	Mamo et al.	May 2012	B2
8182423	Miles et al.	May 2012	B2
8190262	Gerber et al.	May 2012	B2
8195300	Gliner et al.	Jun 2012	B2
8214042	Ozawa et al.	Jul 2012	B2
8214048	Whitehurst et al.	Jul 2012	B1
8214051	Sieracki et al.	Jul 2012	B2
8219196	Torgerson	Jul 2012	B2
8219202	Giftakis et al.	Jul 2012	B2
8224452	Pless et al.	Jul 2012	B2
8224460	Schleicher et al.	Jul 2012	B2
8229565	Kim et al.	Jul 2012	B2
8233990	Goetz	Jul 2012	B2
8255057	Fang et al.	Aug 2012	B2
8311636	Gerber et al.	Nov 2012	B2
8314594	Scott et al.	Nov 2012	B2
8326433	Blum et al.	Dec 2012	B2
8332040	Winstrom	Dec 2012	B1
8337410	Kelleher et al.	Dec 2012	B2
8340786	Gross et al.	Dec 2012	B2
8362742	Kallmyer	Jan 2013	B2
8369943	Shuros et al.	Feb 2013	B2
8380314	Panken et al.	Feb 2013	B2
8382059	Le Gette et al.	Feb 2013	B2
8386048	McClure et al.	Feb 2013	B2
8391972	Libbus et al.	Mar 2013	B2
8396555	Boggs, II et al.	Mar 2013	B2
8412335	Gliner et al.	Apr 2013	B2
8417346	Giftakis et al.	Apr 2013	B2
8423145	Pless et al.	Apr 2013	B2
8423146	Giftakis et al.	Apr 2013	B2
8430805	Burnett et al.	Apr 2013	B2
8433414	Gliner et al.	Apr 2013	B2
8435166	Burnett et al.	May 2013	B2
8447402	Jiang et al.	May 2013	B1
8447408	North et al.	May 2013	B2
8452409	Bachinski et al.	May 2013	B2
8457756	Rahman	Jun 2013	B2
8457758	Olson et al.	Jun 2013	B2
8467875	Bennett et al.	Jun 2013	B2
8480437	Dilmaghanian et al.	Jul 2013	B2
8483839	Wesselink	Jul 2013	B2
8494625	Hargrove	Jul 2013	B2
8509919	Yoo et al.	Aug 2013	B2
8515545	Trier	Aug 2013	B2
8538530	Orinski	Sep 2013	B1
8543223	Sage et al.	Sep 2013	B2
8544322	Minami et al.	Oct 2013	B2
8549015	Barolat	Oct 2013	B2
8554322	Olson et al.	Oct 2013	B2
8555894	Schulman et al.	Oct 2013	B2
8562539	Marino	Oct 2013	B2
8571677	Torgerson et al.	Oct 2013	B2
8577474	Rahman et al.	Nov 2013	B2
8588917	Whitehurst et al.	Nov 2013	B2
8588927	Roy et al.	Nov 2013	B2
8612002	Faltys et al.	Dec 2013	B2
8620436	Parramon et al.	Dec 2013	B2
8626314	Swoyer et al.	Jan 2014	B2
8634904	Kaula et al.	Jan 2014	B2
8634932	Ye et al.	Jan 2014	B1
8644931	Stadler et al.	Feb 2014	B2
8644933	Ozawa et al.	Feb 2014	B2
8644940	Forsell	Feb 2014	B2
8655451	Klosterman et al.	Feb 2014	B2
8655455	Mann et al.	Feb 2014	B2
8672840	Miles et al.	Mar 2014	B2
8694115	Goetz et al.	Apr 2014	B2
8700175	Fell	Apr 2014	B2
8700177	Strother et al.	Apr 2014	B2
8706239	Bharmi et al.	Apr 2014	B2
8706254	Vamos et al.	Apr 2014	B2
8712546	Kim et al.	Apr 2014	B2
8725262	Olson et al.	May 2014	B2
8725269	Nolan et al.	May 2014	B2
8731656	Bourget et al.	May 2014	B2
8738138	Funderburk et al.	May 2014	B2
8738141	Smith et al.	May 2014	B2
8738148	Olson et al.	May 2014	B2
8740783	Gharib et al.	Jun 2014	B2
8744585	Gerber et al.	Jun 2014	B2
8750985	Parramon et al.	Jun 2014	B2
8751008	Carlton et al.	Jun 2014	B2
8761897	Kaula et al.	Jun 2014	B2
8768450	Gharib et al.	Jul 2014	B2
8768452	Gerber	Jul 2014	B2
8774912	Gerber	Jul 2014	B2
8805518	King et al.	Aug 2014	B2
8812116	Kaula et al.	Aug 2014	B2
8825163	Grill et al.	Sep 2014	B2
8825175	King	Sep 2014	B2
8831731	Blum et al.	Sep 2014	B2
8831737	Wesselink	Sep 2014	B2
8849632	Sparks et al.	Sep 2014	B2
8855767	Faltys et al.	Oct 2014	B2
8855773	Kokones et al.	Oct 2014	B2
8868199	Kaula et al.	Oct 2014	B2
8892217	Camps et al.	Nov 2014	B2
8903486	Bourget et al.	Dec 2014	B2
8918174	Woods et al.	Dec 2014	B2
8918184	Torgerson et al.	Dec 2014	B1
8954148	Labbe et al.	Feb 2015	B2
8989861	Su et al.	Mar 2015	B2
9031658	Chiao et al.	May 2015	B2
9044592	Imran et al.	Jun 2015	B2
9050473	Woods et al.	Jun 2015	B2
9089712	Joshi et al.	Jul 2015	B2
9108063	Olson et al.	Aug 2015	B2
9144680	Kaula et al.	Sep 2015	B2
9149635	Denison et al.	Oct 2015	B2
9155885	Wei et al.	Oct 2015	B2
9166321	Smith et al.	Oct 2015	B2
9168374	Su	Oct 2015	B2
9192763	Gerber et al.	Nov 2015	B2
9197173	Denison et al.	Nov 2015	B2
9199075	Westlund	Dec 2015	B1
9205255	Strother et al.	Dec 2015	B2
9209634	Cottrill et al.	Dec 2015	B2
9216294	Bennett et al.	Dec 2015	B2
9227055	Wahlstrand et al.	Jan 2016	B2
9227076	Sharma et al.	Jan 2016	B2
9238135	Goetz et al.	Jan 2016	B2
9240630	Joshi	Jan 2016	B2
9242090	Atalar et al.	Jan 2016	B2
9244898	Vamos et al.	Jan 2016	B2
9248292	Trier et al.	Feb 2016	B2
9259578	Torgerson	Feb 2016	B2
9259582	Joshi et al.	Feb 2016	B2
9265958	Joshi et al.	Feb 2016	B2
9270134	Gaddam et al.	Feb 2016	B2
9272140	Gerber	Mar 2016	B2
9283394	Whitehurst et al.	Mar 2016	B2
9295851	Gordon et al.	Mar 2016	B2
9308022	Chitre et al.	Apr 2016	B2
9308382	Strother et al.	Apr 2016	B2
9314616	Wells et al.	Apr 2016	B2
9320899	Parramon et al.	Apr 2016	B2
9333339	Weiner	May 2016	B2
9352148	Stevenson et al.	May 2016	B2
9352150	Stevenson et al.	May 2016	B2
9358039	Kimmel et al.	Jun 2016	B2
9364658	Wechter	Jun 2016	B2
9375574	Kaula et al.	Jun 2016	B2
9393423	Parramon et al.	Jul 2016	B2
9399137	Parker et al.	Jul 2016	B2
9409020	Parker	Aug 2016	B2
9415211	Bradley et al.	Aug 2016	B2
9427571	Sage et al.	Aug 2016	B2
9427573	Gindele et al.	Aug 2016	B2
9427574	Lee et al.	Aug 2016	B2
9433783	Wei et al.	Sep 2016	B2
9436481	Drew	Sep 2016	B2
9446245	Grill et al.	Sep 2016	B2
9463324	Olson et al.	Oct 2016	B2
9468755	Westlund et al.	Oct 2016	B2
9471753	Kaula et al.	Oct 2016	B2
9480846	Strother et al.	Nov 2016	B2
9492672	Vamos et al.	Nov 2016	B2
9492675	Torgerson et al.	Nov 2016	B2
9492678	Chow	Nov 2016	B2
9498628	Kaemmerer et al.	Nov 2016	B2
9502754	Zhao et al.	Nov 2016	B2
9504830	Kaula et al.	Nov 2016	B2
9522282	Chow et al.	Dec 2016	B2
9533155	Jiang et al.	Jan 2017	B2
9555246	Jiang et al.	Jan 2017	B2
9561372	Jiang et al.	Feb 2017	B2
9592389	Moffitt	Mar 2017	B2
9610449	Kaula et al.	Apr 2017	B2
9615744	Denison et al.	Apr 2017	B2
9623257	Olson et al.	Apr 2017	B2
9636497	Bradley et al.	May 2017	B2
9643004	Gerber	May 2017	B2
9653935	Cong et al.	May 2017	B2
9656074	Simon et al.	May 2017	B2
9656076	Trier et al.	May 2017	B2
9656089	Yip et al.	May 2017	B2
9675809	Chow	Jun 2017	B2
9687649	Thacker	Jun 2017	B2
9707405	Shishilla et al.	Jul 2017	B2
9713706	Gerber	Jul 2017	B2
9717900	Swoyer et al.	Aug 2017	B2
9724526	Strother et al.	Aug 2017	B2
9731116	Chen	Aug 2017	B2
9737704	Wahlstrand et al.	Aug 2017	B2
9744347	Chen et al.	Aug 2017	B2
9750930	Chen	Sep 2017	B2
9757555	Novotny et al.	Sep 2017	B2
9764147	Torgerson	Sep 2017	B2
9767255	Kaula et al.	Sep 2017	B2
9776002	Parker et al.	Oct 2017	B2
9776006	Parker et al.	Oct 2017	B2
9776007	Kaula et al.	Oct 2017	B2
9782596	Vamos et al.	Oct 2017	B2
9802051	Mathur et al.	Oct 2017	B2
9814884	Parker et al.	Nov 2017	B2
9821112	Olson et al.	Nov 2017	B2
9827415	Stevenson et al.	Nov 2017	B2
9827424	Kaula et al.	Nov 2017	B2
9833614	Gliner	Dec 2017	B1
9849278	Spinelli et al.	Dec 2017	B2
9855423	Jiang et al.	Jan 2018	B2
9855438	Parramon et al.	Jan 2018	B2
9872988	Kaula et al.	Jan 2018	B2
9878165	Wilder et al.	Jan 2018	B2
9878168	Shishilla et al.	Jan 2018	B2
9882420	Cong et al.	Jan 2018	B2
9884198	Parker	Feb 2018	B2
9889292	Gindele et al.	Feb 2018	B2
9889293	Siegel et al.	Feb 2018	B2
9889306	Stevenson et al.	Feb 2018	B2
9895532	Kaula et al.	Feb 2018	B2
9895546	Jiang et al.	Feb 2018	B2
9899778	Hanson et al.	Feb 2018	B2
9901284	Olsen et al.	Feb 2018	B2
9901740	Drees et al.	Feb 2018	B2
9907476	Bonde et al.	Mar 2018	B2
9907955	Bakker et al.	Mar 2018	B2
9907957	Woods et al.	Mar 2018	B2
9924904	Cong et al.	Mar 2018	B2
9925381	Nassif	Mar 2018	B2
9931513	Kelsch et al.	Apr 2018	B2
9931514	Frysz et al.	Apr 2018	B2
9950171	Johanek et al.	Apr 2018	B2
9974108	Polefko	May 2018	B2
9974949	Thompson et al.	May 2018	B2
9981121	Seifert et al.	May 2018	B2
9981137	Eiger	May 2018	B2
9987493	Torgerson et al.	Jun 2018	B2
9993650	Seitz et al.	Jun 2018	B2
9999765	Stevenson	Jun 2018	B2
10004910	Gadagkar et al.	Jun 2018	B2
10016596	Stevenson et al.	Jul 2018	B2
10027157	Labbe et al.	Jul 2018	B2
10045764	Scott et al.	Aug 2018	B2
10046164	Gerber	Aug 2018	B2
10047782	Sage et al.	Aug 2018	B2
10052490	Kaula et al.	Aug 2018	B2
10065044	Sharma et al.	Sep 2018	B2
10071247	Childs	Sep 2018	B2
10076661	Wei et al.	Sep 2018	B2
10076667	Kaula et al.	Sep 2018	B2
10083261	Kaula et al.	Sep 2018	B2
10086191	Bonde et al.	Oct 2018	B2
10086203	Kaemmerer	Oct 2018	B2
10092747	Sharma et al.	Oct 2018	B2
10092749	Stevenson et al.	Oct 2018	B2
10092762	Jiang et al.	Oct 2018	B2
10095837	Corey et al.	Oct 2018	B2
10099051	Stevenson et al.	Oct 2018	B2
10103559	Cottrill et al.	Oct 2018	B2
10105542	Jiang et al.	Oct 2018	B2
10109844	Dai et al.	Oct 2018	B2
10118037	Kaula et al.	Nov 2018	B2
10124164	Stevenson et al.	Nov 2018	B2
10124171	Kaula et al.	Nov 2018	B2
10124179	Norton et al.	Nov 2018	B2
10141545	Kraft et al.	Nov 2018	B2
10173062	Parker	Jan 2019	B2
10179241	Walker et al.	Jan 2019	B2
10179244	LeBaron et al.	Jan 2019	B2
10183162	Johnson et al.	Jan 2019	B2
10188857	North et al.	Jan 2019	B2
10195419	Shiroff et al.	Feb 2019	B2
10206710	Kern et al.	Feb 2019	B2
10213229	Chitre et al.	Feb 2019	B2
10220210	Walker et al.	Mar 2019	B2
10226617	Finley et al.	Mar 2019	B2
10226636	Gaddam et al.	Mar 2019	B2
10236709	Decker et al.	Mar 2019	B2
10238863	Gross et al.	Mar 2019	B2
10238877	Kaula et al.	Mar 2019	B2
10244956	Kane	Apr 2019	B2
10245434	Kaula et al.	Apr 2019	B2
10258800	Perryman et al.	Apr 2019	B2
10265532	Carcieri et al.	Apr 2019	B2
10277055	Peterson et al.	Apr 2019	B2
10293168	Bennett et al.	May 2019	B2
10328253	Wells	Jun 2019	B2
10363419	Simon et al.	Jul 2019	B2
10369275	Olson et al.	Aug 2019	B2
10369370	Shishilla et al.	Aug 2019	B2
10376701	Kaula et al.	Aug 2019	B2
10384067	Jiang et al.	Aug 2019	B2
10406369	Jiang et al.	Sep 2019	B2
10448889	Gerber et al.	Oct 2019	B2
10456574	Chen et al.	Oct 2019	B2
10471262	Perryman et al.	Nov 2019	B2
10485970	Gerber et al.	Nov 2019	B2
10493282	Caparso et al.	Dec 2019	B2
10493287	Yoder et al.	Dec 2019	B2
10561835	Gerber	Feb 2020	B2
10589103	Mathur et al.	Mar 2020	B2
10729903	Jiang et al.	Aug 2020	B2
20020002390	Fischell et al.	Jan 2002	A1
20020010498	Rigaux et al.	Jan 2002	A1
20020010499	Rigaux et al.	Jan 2002	A1
20020040185	Atalar et al.	Apr 2002	A1
20020051550	Leysieffer	May 2002	A1
20020051551	Leysieffer et al.	May 2002	A1
20020055761	Mann et al.	May 2002	A1
20020068960	Saberski et al.	Jun 2002	A1
20020077572	Fang et al.	Jun 2002	A1
20020116042	Boling	Aug 2002	A1
20020140399	Echarri et al.	Oct 2002	A1
20020156513	Borkan	Oct 2002	A1
20020169485	Pless et al.	Nov 2002	A1
20020177884	Ahn et al.	Nov 2002	A1
20030028072	Fischell et al.	Feb 2003	A1
20030078633	Firlik et al.	Apr 2003	A1
20030114899	Woods et al.	Jun 2003	A1
20030120323	Meadows et al.	Jun 2003	A1
20030195586	Rigaux et al.	Oct 2003	A1
20030195587	Rigaux et al.	Oct 2003	A1
20030212440	Boveja	Nov 2003	A1
20040098068	Carbunaru et al.	May 2004	A1
20040106963	Tsukamoto et al.	Jun 2004	A1
20040158298	Gliner et al.	Aug 2004	A1
20040210290	Omar-Pasha	Oct 2004	A1
20040250820	Forsell	Dec 2004	A1
20040260357	Vaughan et al.	Dec 2004	A1
20040260358	Vaughan et al.	Dec 2004	A1
20040267137	Peszynski et al.	Dec 2004	A1
20050004619	Wahlstrand et al.	Jan 2005	A1
20050004621	Boveja et al.	Jan 2005	A1
20050021108	Klosterman et al.	Jan 2005	A1
20050049648	Cohen et al.	Mar 2005	A1
20050075693	Toy et al.	Apr 2005	A1
20050075694	Schmeling et al.	Apr 2005	A1
20050075696	Forsberg et al.	Apr 2005	A1
20050075697	Olson et al.	Apr 2005	A1
20050075698	Phillips et al.	Apr 2005	A1
20050075699	Olson et al.	Apr 2005	A1
20050075700	Schommer et al.	Apr 2005	A1
20050085743	Hacker et al.	Apr 2005	A1
20050104577	Matei et al.	May 2005	A1
20050119713	Whitehurst et al.	Jun 2005	A1
20050182454	Gharib et al.	Aug 2005	A1
20050187590	Boveja et al.	Aug 2005	A1
20050240238	Mamo et al.	Oct 2005	A1
20050267546	Parramon et al.	Dec 2005	A1
20060009816	Fang et al.	Jan 2006	A1
20060016452	Goetz et al.	Jan 2006	A1
20060041283	Gelfand et al.	Feb 2006	A1
20060050539	Yang et al.	Mar 2006	A1
20060142822	Tulgar	Jun 2006	A1
20060149345	Boggs, II et al.	Jul 2006	A1
20060200205	Haller	Sep 2006	A1
20060206166	Weiner	Sep 2006	A1
20070025675	Kramer	Feb 2007	A1
20070032834	Gliner et al.	Feb 2007	A1
20070032836	Thrope et al.	Feb 2007	A1
20070049988	Carbunaru et al.	Mar 2007	A1
20070054804	Suty-Heinze	Mar 2007	A1
20070055318	Forsberg et al.	Mar 2007	A1
20070060980	Strother et al.	Mar 2007	A1
20070073357	Rooney et al.	Mar 2007	A1
20070100388	Gerber	May 2007	A1
20070208227	Smith et al.	Sep 2007	A1
20070239224	Bennett et al.	Oct 2007	A1
20070245316	Bates et al.	Oct 2007	A1
20070245318	Goetz et al.	Oct 2007	A1
20070265675	Lund et al.	Nov 2007	A1
20070270921	Strother et al.	Nov 2007	A1
20070276441	Goetz	Nov 2007	A1
20070293914	Woods et al.	Dec 2007	A1
20080027514	DeMulling et al.	Jan 2008	A1
20080065178	Kelleher et al.	Mar 2008	A1
20080065182	Strother et al.	Mar 2008	A1
20080071191	Kelleher et al.	Mar 2008	A1
20080077192	Harry et al.	Mar 2008	A1
20080081958	Denison et al.	Apr 2008	A1
20080132961	Jaax et al.	Jun 2008	A1
20080132969	Bennett et al.	Jun 2008	A1
20080154335	Thrope et al.	Jun 2008	A1
20080161874	Bennett et al.	Jul 2008	A1
20080167694	Bolea et al.	Jul 2008	A1
20080172109	Rahman et al.	Jul 2008	A1
20080177348	Bolea et al.	Jul 2008	A1
20080177365	Bolea et al.	Jul 2008	A1
20080183236	Gerber	Jul 2008	A1
20080215112	Firlik et al.	Sep 2008	A1
20080269740	Bonde et al.	Oct 2008	A1
20080278974	Wu	Nov 2008	A1
20080306325	Burnett et al.	Dec 2008	A1
20090018617	Skelton et al.	Jan 2009	A1
20090036946	Cohen et al.	Feb 2009	A1
20090036951	Heruth et al.	Feb 2009	A1
20090048531	McGinnis et al.	Feb 2009	A1
20090054804	Gharib et al.	Feb 2009	A1
20090076565	Surwit	Mar 2009	A1
20090088816	Harel et al.	Apr 2009	A1
20090105785	Wei et al.	Apr 2009	A1
20090112291	Wahlstrand et al.	Apr 2009	A1
20090118788	Firlik et al.	May 2009	A1
20090157141	Chiao et al.	Jun 2009	A1
20090171381	Schmitz et al.	Jul 2009	A1
20090204176	Miles et al.	Aug 2009	A1
20090227829	Burnett et al.	Sep 2009	A1
20090234302	Hoendervoogt et al.	Sep 2009	A1
20090259273	Figueiredo et al.	Oct 2009	A1
20090281596	King et al.	Nov 2009	A1
20090287272	Kokones et al.	Nov 2009	A1
20090287273	Carlton et al.	Nov 2009	A1
20090306746	Blischak	Dec 2009	A1
20100023084	Gunderson	Jan 2010	A1
20100036445	Sakai et al.	Feb 2010	A1
20100076254	Jimenez et al.	Mar 2010	A1
20100076534	Mock	Mar 2010	A1
20100100158	Thrope et al.	Apr 2010	A1
20100114259	Herregraven et al.	May 2010	A1
20100131030	Firlik et al.	May 2010	A1
20100145427	Gliner et al.	Jun 2010	A1
20100152808	Boggs, II	Jun 2010	A1
20100152809	Boggs, II	Jun 2010	A1
20100160712	Burnett et al.	Jun 2010	A1
20100168820	Maniak et al.	Jul 2010	A1
20100204538	Burnett et al.	Aug 2010	A1
20100222629	Burnett et al.	Sep 2010	A1
20100222847	Goetz	Sep 2010	A1
20100317989	Gharib et al.	Dec 2010	A1
20100318159	Aghassian et al.	Dec 2010	A1
20110004264	Siejko et al.	Jan 2011	A1
20110054562	Gliner	Mar 2011	A1
20110071593	Parker et al.	Mar 2011	A1
20110125214	Goetz et al.	May 2011	A1
20110137378	Klosterman et al.	Jun 2011	A1
20110144468	Boggs et al.	Jun 2011	A1
20110152959	Sherwood et al.	Jun 2011	A1
20110152987	Wahlgren et al.	Jun 2011	A1
20110208263	Balzer et al.	Aug 2011	A1
20110238136	Bourget et al.	Sep 2011	A1
20110251662	Griswold et al.	Oct 2011	A1
20110257701	Strother et al.	Oct 2011	A1
20110278948	Forsell	Nov 2011	A1
20110282416	Hamann et al.	Nov 2011	A1
20110301662	Bar-Yoseph et al.	Dec 2011	A1
20110301667	Olson et al.	Dec 2011	A1
20110313268	Kokones et al.	Dec 2011	A1
20120016447	Zhu et al.	Jan 2012	A1
20120022611	Firlik et al.	Jan 2012	A1
20120029382	Kelleher et al.	Feb 2012	A1
20120041512	Weiner	Feb 2012	A1
20120046712	Woods et al.	Feb 2012	A1
20120071950	Archer	Mar 2012	A1
20120095529	Parramon et al.	Apr 2012	A1
20120101537	Peterson et al.	Apr 2012	A1
20120109258	Cinbis et al.	May 2012	A1
20120116741	Choi et al.	May 2012	A1
20120119698	Karalis et al.	May 2012	A1
20120130448	Woods et al.	May 2012	A1
20120136413	Bonde et al.	May 2012	A1
20120165899	Gliner	Jun 2012	A1
20120197338	Su et al.	Aug 2012	A1
20120197370	Kim et al.	Aug 2012	A1
20120215285	Tahmasian et al.	Aug 2012	A1
20120238893	Farquhar et al.	Sep 2012	A1
20120253422	Thacker et al.	Oct 2012	A1
20120253442	Gliner et al.	Oct 2012	A1
20120259381	Smith et al.	Oct 2012	A1
20120262108	Olson et al.	Oct 2012	A1
20120265267	Blum et al.	Oct 2012	A1
20120271376	Kokones et al.	Oct 2012	A1
20120271382	Arcot-Krishnamurthy et al.	Oct 2012	A1
20120274270	Dinsmoor et al.	Nov 2012	A1
20120276854	Joshi et al.	Nov 2012	A1
20120276856	Joshi et al.	Nov 2012	A1
20120277621	Gerber et al.	Nov 2012	A1
20120277828	O'Connor et al.	Nov 2012	A1
20120277839	Kramer et al.	Nov 2012	A1
20120290055	Boggs, II	Nov 2012	A1
20120296395	Hamann et al.	Nov 2012	A1
20120310299	Kaula et al.	Dec 2012	A1
20120316630	Firlik et al.	Dec 2012	A1
20130004925	Labbe et al.	Jan 2013	A1
20130006325	Woods et al.	Jan 2013	A1
20130006330	Wilder et al.	Jan 2013	A1
20130006331	Weisgarber et al.	Jan 2013	A1
20130023958	Fell	Jan 2013	A1
20130041430	Wang et al.	Feb 2013	A1
20130072998	Su et al.	Mar 2013	A1
20130079840	Su et al.	Mar 2013	A1
20130096641	Strother et al.	Apr 2013	A1
20130096651	Ozawa et al.	Apr 2013	A1
20130123568	Hamilton et al.	May 2013	A1
20130131755	Panken et al.	May 2013	A1
20130148768	Kim	Jun 2013	A1
20130150925	Vamos et al.	Jun 2013	A1
20130165814	Kaula et al.	Jun 2013	A1
20130165991	Kim et al.	Jun 2013	A1
20130172956	Goddard et al.	Jul 2013	A1
20130178758	Kelleher et al.	Jul 2013	A1
20130184773	Libbus et al.	Jul 2013	A1
20130197608	Eiger	Aug 2013	A1
20130207863	Joshi	Aug 2013	A1
20130211479	Olson et al.	Aug 2013	A1
20130226261	Sparks et al.	Aug 2013	A1
20130245719	Zhu et al.	Sep 2013	A1
20130245722	Ternes et al.	Sep 2013	A1
20130261684	Howard	Oct 2013	A1
20130261692	Cardinal et al.	Oct 2013	A1
20130283030	Drew	Oct 2013	A1
20130289659	Nelson et al.	Oct 2013	A1
20130289664	Johanek	Oct 2013	A1
20130289665	Marnfeldt et al.	Oct 2013	A1
20130303828	Hargrove	Nov 2013	A1
20130303942	Damaser et al.	Nov 2013	A1
20130310891	Enrooth et al.	Nov 2013	A1
20130310893	Yoo et al.	Nov 2013	A1
20130310894	Trier	Nov 2013	A1
20130325097	Loest	Dec 2013	A1
20130331909	Gerber	Dec 2013	A1
20130345777	Feldman et al.	Dec 2013	A1
20140062900	Kaula et al.	Mar 2014	A1
20140063003	Kaula et al.	Mar 2014	A1
20140063017	Kaula et al.	Mar 2014	A1
20140067006	Kaula et al.	Mar 2014	A1
20140067014	Kaula et al.	Mar 2014	A1
20140067016	Kaula et al.	Mar 2014	A1
20140067354	Kaula et al.	Mar 2014	A1
20140114385	Nijhuis et al.	Apr 2014	A1
20140142549	Su et al.	May 2014	A1
20140148870	Burnett	May 2014	A1
20140163579	Tischendorf et al.	Jun 2014	A1
20140163580	Tischendorf et al.	Jun 2014	A1
20140163644	Scott et al.	Jun 2014	A1
20140180361	Burdick et al.	Jun 2014	A1
20140180363	Zhu et al.	Jun 2014	A1
20140194771	Parker et al.	Jul 2014	A1
20140194772	Single et al.	Jul 2014	A1
20140194942	Sathaye et al.	Jul 2014	A1
20140194948	Strother et al.	Jul 2014	A1
20140222112	Fell	Aug 2014	A1
20140235950	Miles et al.	Aug 2014	A1
20140236257	Parker et al.	Aug 2014	A1
20140237806	Smith et al.	Aug 2014	A1
20140243931	Parker et al.	Aug 2014	A1
20140249446	Gharib et al.	Sep 2014	A1
20140249599	Kaula et al.	Sep 2014	A1
20140257121	Feldman et al.	Sep 2014	A1
20140277251	Gerber et al.	Sep 2014	A1
20140277268	Lee	Sep 2014	A1
20140277270	Parramon et al.	Sep 2014	A1
20140288374	Miles et al.	Sep 2014	A1
20140288375	Miles et al.	Sep 2014	A1
20140288389	Gharib et al.	Sep 2014	A1
20140296737	Parker et al.	Oct 2014	A1
20140304773	Woods et al.	Oct 2014	A1
20140324144	Ye et al.	Oct 2014	A1
20140343628	Kaula et al.	Nov 2014	A1
20140343629	Kaula et al.	Nov 2014	A1
20140344733	Kaula et al.	Nov 2014	A1
20140344740	Kaula et al.	Nov 2014	A1
20140350636	King et al.	Nov 2014	A1
20140379060	Hershey	Dec 2014	A1
20150028798	Dearden et al.	Jan 2015	A1
20150065047	Wu et al.	Mar 2015	A1
20150066108	Shi et al.	Mar 2015	A1
20150088227	Shishilla et al.	Mar 2015	A1
20150094790	Shishilla et al.	Apr 2015	A1
20150100106	Shishilla et al.	Apr 2015	A1
20150123608	Dearden et al.	May 2015	A1
20150134027	Kaula et al.	May 2015	A1
20150214604	Zhao et al.	Jul 2015	A1
20150231402	Aghassian	Aug 2015	A1
20150360030	Cartledge et al.	Dec 2015	A1
20160045724	Lee et al.	Feb 2016	A1
20160045745	Mathur et al.	Feb 2016	A1
20160045746	Jiang et al.	Feb 2016	A1
20160045747	Jiang et al.	Feb 2016	A1
20160045750	Drees et al.	Feb 2016	A1
20160045751	Jiang et al.	Feb 2016	A1
20160114167	Jiang et al.	Apr 2016	A1
20160121123	Jiang et al.	May 2016	A1
20160199659	Jiang et al.	Jul 2016	A1
20160250462	Kroll et al.	Sep 2016	A1
20170007836	Nassif	Jan 2017	A1
20170128728	Nassif	May 2017	A1
20170189679	Jiang et al.	Jul 2017	A1
20170197079	Illegems et al.	Jul 2017	A1
20170209703	Jiang et al.	Jul 2017	A1
20170340878	Wahlstrand et al.	Nov 2017	A1
20180000344	Melodia	Jan 2018	A1
20180021587	Strother et al.	Jan 2018	A1
20180036477	Olson et al.	Feb 2018	A1
20180117344	Mathur et al.	May 2018	A1
20180133491	Jiang et al.	May 2018	A1
20180243572	Jiang et al.	Aug 2018	A1
20180333581	Nassif	Nov 2018	A1
20190009098	Jiang et al.	Jan 2019	A1
20190269918	Parker	Sep 2019	A1
20190321645	Jiang et al.	Oct 2019	A1
20190351244	Shishilla et al.	Nov 2019	A1
20190358395	Olson et al.	Nov 2019	A1
20200078594	Jiang et al.	Mar 2020	A1

Foreign Referenced Citations (200)

Number	Date	Country
520440	Sep 2011	AT
4664800	Nov 2000	AU
5123800	Nov 2000	AU
2371378	Nov 2000	CA
2554676	Sep 2005	CA
2957967	Nov 2018	CA
1745857	Mar 2006	CN
101495174	Jul 2009	CN
101626804	Jan 2010	CN
101721200	Jun 2010	CN
102164631	Aug 2011	CN
102176945	Sep 2011	CN
102202729	Sep 2011	CN
102215909	Oct 2011	CN
103002947	Mar 2013	CN
103079633	May 2013	CN
102307618	Mar 2014	CN
103796715	May 2014	CN
106999709	Aug 2017	CN
107073257	Aug 2017	CN
107078258	Aug 2017	CN
107148294	Sep 2017	CN
107427675	Dec 2017	CN
107073258	Feb 2020	CN
3146182	Jun 1983	DE
102010006837	Aug 2011	DE
0656218	Jun 1995	EP
1205004	May 2002	EP
1680182	Jul 2006	EP
1904153	Apr 2008	EP
2243509	Oct 2010	EP
1680182	May 2013	EP
1904153	Apr 2015	EP
3180071	Jun 2017	EP
3180072	Jun 2017	EP
3180073	Jun 2017	EP
3180075	Jun 2017	EP
3319683	May 2018	EP
3180072	Nov 2018	EP
3242712	Apr 2019	EP
2395128	Feb 2013	ES
1470432	Apr 1977	GB
1098715	Mar 2012	HK
048370	Jan 1992	JP
2003047179	Feb 2003	JP
2005261662	Sep 2005	JP
2007505698	Mar 2007	JP
2007268293	Oct 2007	JP
4125357	Jul 2008	JP
2008525089	Jul 2008	JP
2011529718	Dec 2011	JP
2013500081	Jan 2013	JP
2013525017	Jun 2013	JP
2013541381	Nov 2013	JP
2013542836	Nov 2013	JP
2014033733	Feb 2014	JP
2014514043	Jun 2014	JP
2017523867	Aug 2017	JP
2017523868	Aug 2017	JP
2017523869	Aug 2017	JP
2017529898	Oct 2017	JP
2018501024	Jan 2018	JP
6602371	Nov 2019	JP
20050119348	Dec 2005	KR
9639932	Dec 1996	WO
9820933	May 1998	WO
9918879	Apr 1999	WO
9934870	Jul 1999	WO
9942173	Aug 1999	WO
0002623	Jan 2000	WO
0019939	Apr 2000	WO
0019940	Apr 2000	WO
0056677	Sep 2000	WO
0001320	Nov 2000	WO
0065682	Nov 2000	WO
0066221	Nov 2000	WO
0069012	Nov 2000	WO
0078389	Dec 2000	WO
0183029	Nov 2001	WO
0193759	Dec 2001	WO
0203408	Jan 2002	WO
0209808	Feb 2002	WO
0137728	Aug 2002	WO
02072194	Sep 2002	WO
02072194	Mar 2003	WO
02078592	Mar 2003	WO
03026739	Apr 2003	WO
03043690	May 2003	WO
03005887	Aug 2003	WO
03035163	Sep 2003	WO
03066162	Mar 2004	WO
2004021876	Mar 2004	WO
2004036765	Apr 2004	WO
03026482	May 2004	WO
2004047914	Jun 2004	WO
2004052448	Jun 2004	WO
2004052449	Jun 2004	WO
2004058347	Jul 2004	WO
2004064634	Aug 2004	WO
2004066820	Aug 2004	WO
2004087256	Oct 2004	WO
03037170	Dec 2004	WO
2004103465	Dec 2004	WO
2005000394	Jan 2005	WO
2005002664	Mar 2005	WO
2005002665	Jun 2005	WO
2005032332	Aug 2005	WO
2005079295	Sep 2005	WO
2005081740	Sep 2005	WO
2005105203	Nov 2005	WO
2005123185	Dec 2005	WO
2006012423	Feb 2006	WO
2006019764	Feb 2006	WO
2005081740	Mar 2006	WO
2006029257	Mar 2006	WO
2006091611	Aug 2006	WO
2006084194	Oct 2006	WO
2006116256	Nov 2006	WO
2006119015	Nov 2006	WO
2006119046	Nov 2006	WO
2006127366	Nov 2006	WO
2005087307	May 2007	WO
2007064924	Jun 2007	WO
2007064936	Jun 2007	WO
2007108863	Sep 2007	WO
2007089394	Nov 2007	WO
2007136694	Nov 2007	WO
2008021524	Feb 2008	WO
2008039242	Apr 2008	WO
2008049199	May 2008	WO
2008042902	Aug 2008	WO
2008106138	Sep 2008	WO
2009021080	Feb 2009	WO
2009042379	Apr 2009	WO
2009051539	Apr 2009	WO
2009051965	Apr 2009	WO
2009042172	Jul 2009	WO
2009091267	Jul 2009	WO
2009134478	Nov 2009	WO
2009137119	Nov 2009	WO
2009137683	Nov 2009	WO
2009139907	Nov 2009	WO
2009139909	Nov 2009	WO
2009139910	Nov 2009	WO
2010014055	Feb 2010	WO
2010014260	Feb 2010	WO
2009139917	Mar 2010	WO
2010042056	Apr 2010	WO
2010042057	Apr 2010	WO
2010065143	Jun 2010	WO
2010111321	Sep 2010	WO
2011011748	Jan 2011	WO
2011053607	May 2011	WO
2011053661	May 2011	WO
2011059565	May 2011	WO
2011100162	Aug 2011	WO
2011139779	Nov 2011	WO
2011153024	Dec 2011	WO
2012054183	Apr 2012	WO
2011156286	May 2012	WO
2011156287	Jun 2012	WO
2012075265	Jun 2012	WO
2012075281	Jun 2012	WO
2012075299	Jun 2012	WO
2012075497	Jun 2012	WO
2012135733	Oct 2012	WO
2012155183	Nov 2012	WO
2012155184	Nov 2012	WO
2012155185	Nov 2012	WO
2012155186	Nov 2012	WO
2012155187	Nov 2012	WO
2012155188	Nov 2012	WO
2012155189	Nov 2012	WO
2012155190	Nov 2012	WO
2012158766	Nov 2012	WO
2013028428	Feb 2013	WO
2013036630	Mar 2013	WO
2013141884	Sep 2013	WO
2013141996	Sep 2013	WO
2013155117	Oct 2013	WO
2013162709	Oct 2013	WO
2013165395	Nov 2013	WO
2014035733	Mar 2014	WO
2012003451	Apr 2014	WO
2014087337	Jun 2014	WO
2014089390	Jun 2014	WO
2014089392	Jun 2014	WO
2014089400	Jun 2014	WO
2014089405	Jun 2014	WO
2014089485	Jun 2014	WO
2013162708	Jul 2014	WO
2014151160	Sep 2014	WO
2014161000	Oct 2014	WO
2014172381	Oct 2014	WO
2016025909	Feb 2016	WO
2016025912	Feb 2016	WO
2016025913	Feb 2016	WO
2016025915	Feb 2016	WO
2016112398	Jul 2016	WO
2017011305	Jan 2017	WO

Non-Patent Literature Citations (75)

Entry
US 9,601,939 B2, 03/2017, Cong et al. (withdrawn)
Bu-802a: How Does Rising Internal Resistance Affect Performance? Understanding the Importance of Low Conductivity, Battery University, Available Online at: https://batteryuniversity.com/learn/article/rising_internal_resistance, Accessed from Internet on May 15, 2020, 10 pages.
DOE Handbook: Primer on Lead-Acid Storage Batteries, United States Department of Energy, Available Online at: htt12s://www.stan dards.doe.gov/standards- documents/ I 000/1084-bhdbk-1995/@@images/file, Sep. 1995, 54 pages.
Medical Electrical Equipment—Part 1: General Requirements for Safety, British Standard, BS EN 60601-1:1990-BS5724-1:1989, Mar. 1979, 200 pages.
Summary of Safety and Effectiveness, Medtronic InterStim System for Urinary Control, Apr. 15, 1999, pp. 1-18.
The Advanced Bionics Precision™ Spinal Cord Stimulator System, Advanced Bionics Corporation, Apr. 27, 2004, pp. 1-18.
UL Standard for Safety for Medical and Dental Equipment, Underwriters Laboratories 544, 4th edition, Dec. 30, 1998, 128 pages.
Barnhart et al., “A Fixed-Rate Rechargeable Cardiac Pacemaker”, Applied Physics Laboratory Technical Digest, Jan.-Feb. 1970, pp. 2-9.
Benditt et al., “A Combined Atrial/Ventricular Lead for Permanent Dual-Chamber Cardiac Pacing Applications”, Chest, vol. 83, No. 6, Jun. 1983, pp. 929-931.
Boiocchi et al., “Self-Calibration in High Speed Current Steering CMOS D/A Converters”, Advanced A-D and D-A Conversion Techniques and their Applications, Second International Conference on Cambridge, Jul. 1994, pp. 148-152.
Bosch et al., “Sacral (S3) Segmental Nerve Stimulation as a Treatment for Urge Incontinence in Patients with Detrusor Instability: Results of Chronic Electrical Stimulation Using an Implantable Neural Prosthesis”, The Journal of Urology, vol. 154, No. 2, Aug. 1995, pp. 504-507.
Boyce et al., “Research Related to the Development of an Artificial Electrical Stimulator for the Paralyzed Human Bladder: A Review”, The Journal of Urology, vol. 91, No. 1, Jan. 1964, pp. 41-51.
Bradley et al., “Further Experience with the Radio Transmitter Receiver Unit for the Neurogenic Bladder”, Journal of Neurosurgery, vol. 20, No. 11, Nov. 1963, pp. 953-960.
Broggi et al., “Electrical Stimulation of the Gasserian Ganglion for Facial Pain: Preliminary Results”, Acta Neurochirurgica, vol. 39, 1987, pp. 144-146.
Buhlmann et al., “Modeling of a Segmented Electrode for Desynchronizing Deep Brain Stimulation”, Frontiers in Neuroengineering, vol. 4, No. 15, Dec. 8, 2011, 8 pages.
Cameron et al., “Effects of Posture on Stimulation Parameters in Spinal Cord Stimulation”, Neuromodulation, vol. 1, No. 4, Oct. 1998, pp. 177-183.
Connelly et al., “Atrial Pacing Leads Following Open Heart Surgery: Active or Passive Fixation?”, Pacing and Clinical Electrophysiology, vol. 20, No. 10, Oct. 1997, pp. 2429-2433.
Fischell , “The Development of Implantable Medical Devices at the Applied Physics Laboratory”, Johns Hopkins Applied Physics Laboratory Technical Digest, vol. 13 No. 1, 1992, pp. 233-243.
Gaunt et al., “Control of Urinary Bladder Function with Devices: Successes and Failures”, Progress in Brain Research, vol. 152, 2006, pp. 1-24.
Ghovanloo et al., “A Small Size Large Voltage Compliance Programmable Current Source for Biomedical Implantable Microstimulators”, Proceedings of the 25th Annual International Conference of the Institute of Electrical and Electronics Engineers, Engineering in Medicine and Biology Society, Sep. 17-21, 2003, pp. 1979-1982.
Gudnason , “A Low-Power ASK Demodulator for Inductively Coupled Implantable Electronics”, Solid-State Circuits Conference, 2000, Esscirc 00, Proceedings of the 26rd European, Institute of Electrical and Electronics Engineers, Sep. 19, 2000, pp. 385-388.
Hansen et al., “Urethral Sphincter Emg as Event Detector for Neurogenic Detrusor Overactivity”, IEEE Transactions on Biomedical Engineering, vol. 54, No. 7, Jul. 31, 2007, pp. 1212-1219.
Helland , “Technical Improvements to be Achieved by the Year 2000: Leads and Connector Technology”, Rate Adaptive Cardiac Pacing, Springer Verlag, 1993, pp. 279-292.
Hidefjall , “The Pace of Innovation—Patterns of Innovation in the Cardiac Pacemaker Industry”, Linkoping University Press, 1997, 398 pages.
Ishihara et al., “A Comparative Study of Endocardial Pacemaker Leads”, Cardiovascular Surgery, Nagoya Ekisaikai Hospital, 1st Dept. of Surgery, Nagoya University School of Medicine, 1981, pp. 132-135.
Jonas et al., “Studies on the Feasibility of Urinary Bladder Evacuation by Direct Spinal Cord Stimulation. I. Parameters of Most Effective Stimulation”, Investigative Urology, vol. 13, No. 2, 1975, pp. 142-150.
Kakuta et al., “In Vivo Long Term Evaluation of Transcutaneous Energy Transmission for Totally Implantable Artificial Heart”, American Society for Artificial Internal Organs Journal, Mar.-Apr. 2000, pp. 1-2.
Lazorthes et al., “Chronic Stimulation of the Gasserian Ganglion for Treatment of Atypical Facial Neuralgia”, Pacing and Clinical Electrophysiology, vol. 10, Jan.-Feb. 1987, pp. 257-265.
Lewis et al., “Early Clinical Experience with the Rechargeable Cardiac Pacemaker”, The Annals of Thoracic Surgery, vol. 18, No. 5, Nov. 1974, pp. 490-493.
Liu et al., “A Neuro-Stimulus Chip with Telemetry Unit for Retinal Prosthetic Device”, Institute of Electrical and Electronics Engineers Journal of Solid-State Circuits, vol. 35, No. 10, Oct. 2000, 4 pages.
Love et al., “Experimental Testing of a Permanent Rechargeable Cardiac Pacemaker”, The Annals of Thoracic Surgery, vol. 17, No. 2, Feb. 1, 1974, pp. 152-156.
Love , “Pacemaker Troubleshooting and Follow-up”, Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy, Chapter 24, 2007, pp. 1005-1062.
Madigan et al., “Difficulty of Extraction of Chronically Implanted Tined Ventricular Endocardial Leads”, Journal of the American College of Cardiology, vol. 3, No. 3, Mar. 1984, pp. 724-731.
McLennan , “The Role of Electrodiagnostic Techniques in the Reprogramming of Patients with a Delayed Suboptimal Response to Sacral Nerve Stimulation”, International Urogynecology Journal, vol. 14, No. 2, Jun. 2003, pp. 98-103.
Meglio , “Percutaneously Implantable Chronic Electrode for Radiofrequency Stimulation of the Gasserian Ganglion. A Perspective in the Management of Trigeminal Pain”, Acta Neurochirurgica, vol. 33, 1984, pp. 521-525.
Meyerson , “Alleviation of Atypical Trigeminal Pain by Stimulation of the Gasserian Ganglion via an Implanted Electrode”, Acta Neurochirurgica Supplementum , vol. 30, 1980, pp. 303-309.
Mingming , “Development of an Implantable Epidural Spinal Cord Stimulator With Emg Biofeedback”, China Master's Theses Full-text Database: Engineering Technology, vol. 2, No. 6, May 23, 2013, 64 pages.
Mitamura et al., “Development of Transcutaneous Energy Transmission System”, Available Online at https://www.researchgate.net/publication/312810915 Ch.28, Jan. 1988, pp. 265-270.
Nag et al., “Flexible Charge Balanced Stimulator With 5.6 fC Accuracy for 140 nC Injections”, Institute of Electrical and Electronics Engineers Transactions on Biomedical Circuits and Systems, vol. 7, No. 3, Jun. 2013, pp. 266-275.
Nakamura et al., “Biocompatibility and Practicality Evaluations of Transcutaneous Energy Transmission Unit for the Totally Implantable Artificial Heart System”, Journal of Artificial Organs, vol. 27, No. 2, 1998, pp. 347-351.
Nashold et al., “Electromicturition in Paraplegia. Implantation of a Spinal Neuroprosthesis”, Archives of Surgery., vol. 104, Feb. 1972, pp. 195-202.
Noblett , “Neuromodulation and the Role of Electrodiagnostic Techniques”, International Urogynecology Journal, vol. 21, No. 2, Dec. 2010, 13 pages.
Painter et al., “Implantation of an Endocardial Tined Lead to Prevent Early Dislodgement”, The Journal of Thoracic and Cardiovascular Surgery, vol. 77, No. 2, Feb. 1979, pp. 249-251.
Paralikar et al., “A Fully Implantable and Rechargeable Neurostimulation System for Animal Research”, 7th Annual International Institute of Electrical and Electronics Engineers Engineering in Medicine and Biology Society, Conference of Neural Engineering, Apr. 22-24, 2015, pp. 418-421.
Perez , “Lead-Acid Battery State of Charge vs. Voltage”, Available Online at http://www.rencobattery.com/resources/SOC vs-Voltage.pdf, Aug.-Sep. 1993, 5 pages.
Schaldach et al., “A Long-Lived, Reliable, Rechargeable Cardiac Pacemaker”, Engineering in Medicine, vol. 1: Advances in Pacemaker Technology, 1975, 34 pages.
Scheuer-Leeser et al., “Polyurethane Leads: Facts and Controversy”, PACE, vol. 6, Mar.-Apr. 1983, pp. 454-458.
Sivaprakasam et al., “A Variable Range Bi-Phasic Current Stimulus Driver Circuitry for an Implantable Retinal Prosthetic Device”, Institute of Electrical and Electronics Engineers Journal of Solid-State Circuits, Institute of Electrical and Electronics Engineers Service Center, Piscataway, vol. 40, No. 3, Mar. 1, 2005, pp. 763-771.
Smith , “Changing Standards for Medical Equipment”, UL 544 and UL 187 vs. UL 2601 (“Smith”), 2002, 8 pages.
Tanagho et al., “Bladder Pacemaker: Scientific Basis and Clinical Future”, Urology, vol. 20, No. 6, Dec. 1982, pp. 614-619.
Tanagho , “Neuromodulation and Neurostimulation: Overview and Future Potential”, Translational Androl Urol, vol. 1, No. 1, 2012, pp. 44-49.
Torres et al., “Electrostatic Energy-Harvesting and Battery-Charging CMOS System Prototype”, IEEE Transactions on Circuits and Systems I: Regular Papers, vol. 56, No. 9, Dec. 22, 2008, pp. 1938-1948.
Van Paemel , “High-Efficiency Transmission for Medical Implants”, Institute of Electrical and Electronics Engineers Solid-State Circuits Magazine, vol. 3, No. 1, Jan. 1, 2011, pp. 47-59.
Von Arx et al., “A Wireless Single-Chip Telemetry-Powered Neural Stimulation System”, Institute of Electrical and Electronics Engineers International Solid-State Circuits Conference, ISSCC99, Session 12, Paper TP 12.6, Feb. 16, 1999, pp. 215-216.
Wang et al., “A 140-dB CMRR Low-Noise Instrumentation Amplifier for Neural Signal Sensing”, Asia-Pacific Conference on Circuits and Systems, Institute of Electrical and Electronics Engineers Asia Pacific Conference, Dec. 1, 2006, pp. 696-699.
Young , “Electrical Stimulation of the Trigeminal Nerve Root for the Treatment of Chronic Facial Pain”, Journal of Neurosurgery, vol. 83, No. 1, Jul. 1995, pp. 72-78.
U.S. Appl. No. 14/827,067, filed Aug. 14, 2015.
U.S. Appl. No. 14/827,074, filed Aug. 14, 2015.
U.S. Appl. No. 14/827,081, filed Aug. 14, 2015.
U.S. Appl. No. 14/827,095, filed Aug. 14, 2015.
U.S. Appl. No. 14/827,108, filed Aug. 14, 2015.
U.S. Appl. No. 14/991,649, filed Jan. 8, 2016.
U.S. Appl. No. 14/991,752, filed Jan. 8, 2016.
U.S. Appl. No. 14/991,784, filed Jan. 8, 2016.
U.S. Appl. No. 62/038,122, filed Aug. 15, 2014.
U.S. Appl. No. 62/038,131, filed Aug. 15, 2014.
U.S. Appl. No. 62/041,611, filed Aug. 25, 2014.
U.S. Appl. No. 62/101,666, filed Jan. 9, 2015.
U.S. Appl. No. 62/101,782, filed Jan. 9, 2015.
U.S. Appl. No. 62/101,884, filed Jan. 9, 2015.
U.S. Appl. No. 62/101,888, filed Jan. 9, 2015.
U.S. Appl. No. 62/101,897, filed Jan. 9, 2015.
U.S. Appl. No. 62/101,899, filed Jan. 9, 2015.
U.S. Appl. No. 62/110,274, filed Jan. 30, 2015.
U.S. Appl. No. 62/191,134, filed Jul. 10, 2015.

Related Publications (1)

	Number	Date	Country
	20200372996 A1	Nov 2020	US

Provisional Applications (1)

	Number	Date	Country
	62852875	May 2019	US

Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract